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Summary
Summary
Immunoglobulin gamma (IgG) molecules are preeminent effector proteins of the humoral 
immune system. Their antigen-binding fragment, Fab, recognizes cognate antigens with high 
specificity and their constant region (Fc) conveys pro-inflammatory effector functions such 
as recruitment and activation of leukocytes through engagement with Fcγ receptors (FcγRs) 
and complement activation. However, high doses of pooled, monomeric IgG depict anti-
inflammatory activity as reflected by the therapeutic efficacy of intravenous immunoglobulins 
(IVIG) in several autoimmune diseases. The underlying mechanisms that confer these anti-
inflammatory activity are incompletely understood. Experimental data provide evidence that 
IgG Fc-linked glycan structures regulate antibody-mediated effector functions. As such, the 
presence of terminal sialic acid acts as a molecular switch shifting IgG activity from a pro-
inflammatory to an anti-inflammatory pathway. We investigated mediators and regulators of 
IgG functions such as FcγR expression and Fc-linked glycan structures in patients with chronic 
inflammatory demyelinating polyneuropathy (CIDP), an autoimmune disease of the peripheral 
nervous system in which humoral immune responses are central in mediating tissue damage. 
Compared to healthy individuals, patients with CIDP showed increased expression levels of 
activating FcgRs and decreased expression of inhibitory FcγRIIB indicating that the FcγR 
regulatory system is disturbed. Clinically effective IVIG therapy partially restored deregulated 
FcγR expression. In addition, induction of IgG Fc-sialylation was associated with clinical 
disease remission over time. We demonstrate that IgG Fc sialylation does not affect antibody-
dependent cell-mediated cytotoxicity (ADCC) but impairs the efficacy of IgG molecules to 
activate complement by inhibition of C1q binding to galactosylated IgG. We conclude from 
these data that inhibition of CDC represents an FcγR-independent mechanism by which Fc-
sialylated glycovariants might limit pro-inflammatory IgG effector functions. Thus, our data 
support the development of strategies that target increased Fc-sialylation for the treatment of 
human autoimmune diseases. In addition, we found that dimeric antigen-binding fragments, 
F(ab’)2, are sufficient to prevent disease development in a murine model of T cell mediated 
autoimmunity, indicating that more than one mechanism is responsible for the clinical efficacy 
of IVIG.
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Zusammenfassung
Zusammenfassung
Immunoglubulin-gamma (IgG) Antikörper sind wichtige Effektor-Proteine des humoralen 
Immunsystems. Über ihre antigen-bindenden Regionen (Fab) erkennen sie Zielstrukturen 
mit hoher Spezifität und die konstante Region (Fc) vermittelt Effektormechanismen wie die 
Aktvierung von Leukozyten über Fcg-Rezeptoren (FcgR) oder Komplementaktivierung. 
Darüber hinaus wirken hohe Dosen intravenös appliziertem IgG (IVIG) anti-inflammatorisch, 
eine Eigenschaft die zur Behandlung von Autoimmunerkrankungen eingesetzt wird. Welche 
Mechanismen allerdings dafür verantwortlich sind, ist unzureichend bekannt. Untersuchungen 
haben gezeigt, dass die Struktur des Zuckers in der Fc-Region die Funktionalität von Antikörpern 
beeinflusst. So wird der Anwesenheit von Sialylsäure zugeschrieben, dass sie als molekularer 
Schaltmechanismus von pro- auf anti-inflammatorisch fungiert. Wir haben FcgR und IgG-
Fc Zuckerstrukturen in Patienten mit Chronischer Inflammatorischer Demyelinisierender 
Polyneuropathie (CIDP) untersucht, einer Erkrankung des peripheren Nervensystems in der 
humorale Immunantworten von zentraler Bedeutung sind. Im Vergleich zu gesunden Individuen 
hatten CIDP Patienten mehr aktivierende FcgR auf der Zelloberfläche und weniger inhibitorische 
FcgRIIB, was ein regulatorisches Ungleichgewicht suggeriert. Behandlung mit IVIG führte zu 
einer teilweisen Normalisierung der FcgR Expression. Ausserdem konnten wir zeigen, dass die 
vermehrte Präsenz von Sialylsäure am IgG-Fc Zucker mit klinischer Remission der Erkrankung 
korreliert. Die Analyse von Antikörpern mit unterschiedlichen Fc-Zuckervarianten zeigte, 
dass komplement-vermittelte (CDC), nicht aber zell-vermittelte Zytotoxizität (ADCC) durch 
die Anwesenheit von Sialylsäure verringert wird. Wir schlussfolgern daraus, dass Sialylsäure 
die pro-inflammatorische Aktivität von IgG durch Reduktion von Komplement-Aktivierung 
vermindert. Dies empfiehlt die Entwicklung von therapeutischen Strategien zur Induktion von 
IgG-Fc Sialylierung. Zusätzlich konnten wir in murinen modellsystems für T Zell vermittelte 
Autoimmunität nachweisen, dass isolierte antigen-bindende Fragmente anti-inflammatorisch 
wirken können. Dies zeigt, dass die therapeutische Wirksamkeit von IVIG wahrscheinlich nicht 
auf einen einzelnen Mechanismus zurückzuführen ist sondern auf der Kombination mehrerer 
beruht.
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1Introduction
1. Introduction
1.1 Basic concepts and components of the immune system 
In biology, immunity is defined as the resistance to develop a pathologic condition.
The fight against biological invasion needs to be balanced with maintenance of immune 
homeostasis to avoid overwhelming inflammation and autoimmune disease. An important 
implication to fulfill this function is the ability to distinguish “normal” self from non-self, a 
property that even the most primitive eukaryotes possess [1]. Physical barriers such as the skin 
are the first preventive measures against the invasion of foreign organisms. If they fail, an active 
immune response is initiated by cellular and humoral components of the innate immune system 
through recognition of pathogen associated molecular patterns (PAMPs). Joint host-pathogen 
evolution led to the development of germline-encoded PAMP-recognizing molecules however, 
in parallel, pathogens evolved to avoid recognition and actively interfere with the immune 
system. As a result, innate immunity is insufficient for host protection. 
This led to the development of a second line of defense found in all jawed vertebrates: the 
adaptive immune system [2]. One important feature of adaptive immunity is that its specificity 
is not restricted by the germline, instead somatic DNA modification allows for the directed 
generation of novel antigen binding receptors. Besides inactivation of invading organisms, the 
phagocytes of the innate immune system process and present pathogen-derived components to 
lymphocytes (T and B cells), the cellular members of the adaptive immune system. Whereas 
T cells developed to recognize mostly linear protein epitopes presented on the cell surface of 
antigen presenting cells and virus or tumor transformed cells, B cells recognize antigens in their 
native confirmation. A complex selection process prevents the development of cells reactive to 
self-antigens while enabling specific high-affinity recognition of foreign antigens. The second 
cardinal feature of adaptive immunity is the transition of successfully developed antigen-specific 
T or B cells into a pool of long-lived cells. Re-encounter of the same antigen (for example by 
a second infection with the same pathogen) leads to reactivation and subsequent proliferation 
of the respective cells thereby enabling a more rapid secondary response. The communication 
between innate and adaptive immunity is bidirectional and both systems depend on each other 
for functionality. A list of the basic components of the immune system is given in table 1.1.
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Type Mediator Function
Innate 
immunity
Barriers Physical barrier Prevention of microbe entry
Antibiotics (defensins, 
cathelicidins)
Prevention of microbe entry
Intraepithelial 
leukocytes
Prevention of microbe entry
Cells Granulocytes Phagocytosis and killing of microbes
Macrophages Phagocytosis and killing of microbes
NK cells Killing of infected and tumor transformed cells
Dendritic cells antigen presentation to T & B cells
Soluble 
mediators
Complement Killing of microbes, opsonization of microbes, activa-
tion of leukocytes
Mannose-binding 
lectin
Opsonization of microbes, activation of complement
C-reactive protein Opsonization of microbes, activation of complement
Cytokines & 
chemokines
Inhibition of microbial spread, regulation of leukocyte 
homing, differentiation and proliferation
Adaptive 
immunity
Cells B 
cells
Conventional 
B cells
Antibody production
Regulatory
B cells
Regulation of adaptive immune responses (maintenance 
of self-tolerance)
T 
cells
CD4+ T cells Activation of macrophages and dendritic cells,
stimulation and regulation of B & T cell responses
CD8+ T cells Killing of infected and tumor transformed cells
FoxP3+ T cells Suppression of T cell function (maintenance of self-
tolerance)
Soluble 
mediators
Antibodies Neutralization, opsonization and phagocytosis of mi-
crobes, CDC, ADCC
Cytokines & 
chemokines
Inhibition of microbial spread, regulation of leukocyte 
homing, differentiation and proliferation
1.2 Antibodies 
1.2.1 The history of antibodies: From serum therapy to clonal selection and monoclonal 
antibodies
At the end of the 19th century, Emil Behring and Shibasabura Kitasato made the landmark 
finding that transfer of serum from animals immunized with diphtheria toxin can be used 
to protect animals from an otherwise lethal dose of toxin [5]. This was the first confirmed 
description of passive immunization and the basis for a new field of research: immunology [6]. 
The protective effect was found to be specific as immunization with one toxin would only lead 
to protection against the very same toxin. The urgent need for treatment of diphtheria resulted 
in rapid attempts to translate this finding into clinical use. Immunization of sheep and horses 
Table 1.1 Components of the immune system
Adapted from [3, 4].
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were the first sources of serum and treatment showed promising results but fever, rashes and 
also serious anaphylactic reactions frequently occurred. Soon after, the protein fraction of the 
serum was identified to mediate protection [5] and 1897 Paul Ehrlich proposed a molecular 
mechanism, the side-chain theory. In brief, this theory is based on the presence of cell-surface 
molecules (side-chains) with different structural properties normally used for the uptake of 
products. Coincidental recognition of a toxin induces the cell to produce more of the side-chain 
resulting in its release into the circulation. These soluble side-chains would then be able to 
bind the toxin before it can bind to other cells and thereby render it innocuous [7, 8]. Using our 
current wording, cell-surface bound side-chains would be called B cell receptors (being a cell-
surface bound antibody) and soluble side-chains would be secreted antibodies. 
But it still took a few years until the chemical nature of antibodies was elucidated. Michael 
Heidelberger unequivocally proved that antibodies are proteins [9] and in 1939 his student 
Elvin Kabat found that smaller and larger antibodies exist (referring to IgG and IgM) [10, 11]. 
Subsequently, purification of a human serum fraction enriched for immune gamma globulin 
(IgG) largely reduced the side effects and was used for the first time in 1944 to treat measles 
[12, 13]. Soon after, plasma cells were identified as a cellular source of gamma globulins [14]. 
Finally Rodney Porter recognized the presence of an antigen-binding region (Fab, fragment 
antigen binding) and an Fc (fragment crystallizable) [15] and Gerald Edelman solved the basic 
structure of antibodies being composed of two heavy and two light chains linked by disulfide 
bonds [16-18]. At the same time, Macfarlane Burnet formulated the “clonal selection theory”, 
anticipating many of the basic aspects of our current understanding about the development of 
antibody diversity [19]. He postulated that antibodies are selected from a pre-existing pool and 
are purposefully modified in order to recognize a target antigen [19,20]. 
One of the most significant advances for modern research and medicine was made in 1975 when 
Köhler and Milstein developed the hybridoma technique allowing the continuous culture of an 
antibody-secreting cell with defined specificity [21]. First attempts for clinical use  resulted 
in the development of Muronomab-CD3, the first mouse anti-human monoclonal antibody 
approved for the application in humans to treat leukemia [22, 23]. However, like animal serum 
transfer at the turn of the 19th century, treatment of humans with murine antibodies led to 
serious side effects including anaphylactic shock [24] and the development of human-anti-
mouse antibodies abrogated therapeutic efficacy [23, 25]. Advances in molecular cloning and 
expression techniques allowed the generation of monoclonal antibodies with a human constant 
region (chimeric antibodies) [26] and later fully human antibodies were established [27]. More 
than 100 years after Paul Ehrlich`s idea of developing a “magic bullet” to specifically target a 
molecular structure [28] we are now able to do so and continuous efforts are made to select new 
targets and optimize the therapeutic properties of antibodies. 
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1.2.2 The role of antibodies within the immune system 
Immunoglobulins are amongst to the most abundant proteins found in serum [29]. 
Producing these vast amounts is a huge investment of the body which highlights the 
essential role of antibodies in the immune system. During a primary infection, pre-existing 
mostly germline-encoded low-affinity antibodies (natural antibodies) work in an innate-
like manner and recognize PAMPs. This can neutralize toxins or microbes by blocking 
the structures required for their toxic or pathologic action. In addition, antibody-driven 
activation of the complement system (discussed in more detail below) and cytotoxic 
cells can kill invading organisms [30]. At the same time, immunoglobulins increase the 
visibility of the pathogen for the body, a process called opsonization. Thereby, pathogens 
and infected cells are “marked” by antibodies and complement components leading 
to the activation of phagocytes such as macrophages and DCs which engulf, destroy, 
process and transport the pathogen to secondary lymphoid organs for the initiation of 
an adaptive immune response. This results in the generation of B cells producing more 
potent, higher affinity antibodies and antigen-specific T cells which both may enter the 
memory pool and provide superior protection upon re-encounter of the same pathogen 
(see chapter 1.1.4). The protective mechanisms mediated by different types of antibodies 
are discussed in more detail in chapters 1.2.5 and 1.3.  
1.2.3 Antibody structure 
Antibodies are closely related glycoproteins that consist of four polypeptide chains consisting 
of two identical heavy chains (HC) and two identical light chains (LC) (figure 1.1) [31]. 
Differences among the antibody variants (isotypes) are discussed later. The tertiary protein 
structure of both HC an LC is characterized by the immunoglobulin (Ig-) fold, which is composed 
of two disulfide-bond stabilized b-sheets that form a barrel-like structure (b barrel) [32]. The 
N-terminal Ig domain of each HC and LC contains the variable regions (complementary 
determining regions, CDRs) in charge of the diversity and specificity of antigen recognition. 
These Ig domains are called VH (variable region; heavy chain) and VL (variable region; light 
chain). The remaining Ig domain of the LC is called CL and those of the HC CH1 to CH3 (and 
CH4 for some isotypes). Disulfide bonds in between the two HCs as well as the HCs and LCs 
covalently link the individual polypeptides and stabilize their quaternary structure. Several 
genes encode for different HC sequences that significantly impact the antibody structure and 
function (see chapter 1.2.5). In contrast, only two light chain genes (k an l) exist and no major 
differences have been identified. Based on early proteolytic and structural studies, antibodies 
are traditionally divided into two regions. Each of the two identical fragment antigen binding 
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(Fab) regions consists of a complete LC and the two N-terminal Ig domains of a HC. If the 
two Fab regions are still linked to each other by the hinge-region disulfide bonds, the fragment 
is called F(ab’)2. The C-terminal fragment cristallyzable (Fc) encompasses CH2 and CH3 (and 
CH4) and varies based on the antibody isotype (see chapter 1.1.4). Fab and Fc are joined by 
the hinge region  (except for IgM and IgE) which provides conformational flexibility to the 
antibody. Another important structural component are glycans which account for 4-18 % of the 
total weight [31]. At least one N-glycan is located in the constant region of each HC [1]. VH and 
CH regions can occasionally contain glycans and some antibody subclasses possess O-glycans 
[33]. 
CH2
CH3
C L
V L
C H
1
V H
Fc
Fab
Hinge
Glycan
Complementary 
determining 
regions (CDRs)
Interchain 
disulfide bonds
Intrachain
disulfide bond
Heavy chain
Light chain
Figure 1.1 Basic antibody structure
A prototypic (IgG1) antibody composed of two heavy and light chains and two 
glycans is shown. Structural and functional components are indicated in grey. 
Modified from [1, 31].
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1.2.4 B cell maturation: Generation of antibody diversity and memory
B lineage cells are the cellular origin of antibodies. They arise from hematopoietic progenitor 
cells and develop in the bone marrow until the immature B cell stage when they leave the bone 
marrow, enter circulation and home to the spleen or other secondary lymphoid organs. In the 
periphery, B cells further differentiate towards the mature naïve B cell stage [3]. The human 
immunoglobulin repertoire of naïve (pre-immune) B cells is estimated to exceed 1012 different 
antibody molecules [34]. Encoding this diversity in the genome would not leave much space 
for anything else [5]. This seemingly paradox situation made Dreyer and Bennett postulate that 
“immunologically competent cells have evolved a pattern of somatic genetic behavior which 
is radically different from anything normally found in modern molecular genetics” [35]. Their 
suggested mechanism involved  “a kind of genetic scrambling process” [35] and the subsequent 
combination of the antibody variable regions with a constant region [35]. Today, the genetic 
scrambling process is called V(D)J recombination referring to the three genomic segments V, 
D and J which together encode the antibody variable region. D is in brackets because these 
segments exist only in the heavy chain sequences and not in the light chains [3, 36, 37]. Several 
copies of each segment, each composed of a different nucleotide sequence, are present in the 
genome. Combination of different segments with each other results in the diversity of the 
immature B cell receptor (BCR) [3, 36]. Expression of a functional non self-reactive immature 
B cell receptor (cell-surface bound IgD and IgM) allows the cell to exit the bone marrow. In 
the spleen, B cells are again positively and negatively selected for a functional but non self-
reactive BCR expression [38-40] before they enter the mature naïve B cell stage [41, 42]. 
Further development is only induced by the recognition of a cognate antigen and depending 
on the nature of the antigen as well as the anatomic location within the body. Two distinct 
developmental pathways can occur: T cell independent maturation in the gut and marginal 
zone of the spleen resulting in B cells producing antibodies which recognize mainly polymeric 
non-protein antigens, or T cell dependent maturation in a germinal center as typically induced 
by protein antigens [3, 43]. The latter is characterized by further diversification of the BCR 
repertoire via affinity maturation. During this process, antigen and helper-T cell activated B cells 
migrate from the outer regions (“T cell zone”) of secondary lymphoid organs into the follicle 
and proliferate extensively. This usually happens 4 to 7 days after the first antigen encounter 
and marks the beginning of a germinal center reaction. The induction of activation-induced 
deaminase (AID) by CD40-CD40L interactions between T and B cells results in the generation 
of cytosine (C) to uracil (U) mutation preferentially in the three highly susceptible regions 
(complementary determining regions 1-3, CDR1-3) of the rearranged heavy and light chain 
immunoglobulin V(D)J DNA. During DNA replication Us (usually only present in RNA and 
not DNA) are exchanged for thymidines (Ts) generating C to T mutation or Us may be excised 
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by uracil N-glycosylase following error-prone repair resulting in substitution by any of the four 
DNA bases [3]. This is called somatic hypermutation (SHM) and aims to generate antibodies 
which recognize their cognate antigen with increased affinity. Following proliferation and SHM 
in the “dark zone” of the germinal center, newly developed B cells migrate to the light zone 
where they encounter antigen presented on the surface of follicular DCs. Only those B cells 
which recognize the antigen with high affinity are positively selected and survive, all others 
undergo apoptosis. Positive selection can either result in another round of SHM and selection or 
B cells exit the germinal center and further differentiate [44]. Before this happens they undergo 
yet another diversification: the constant region of the antibody HCs is responsible to combine 
the specific antigen recognition with humoral and cellular effector functions. Depending on the 
requirements of the immune response, the functional properties of an antibody can be changed 
by a process called “class switching” or “isotype switching”. Thereby, the genomic region 
encoding for the desired antibody constant region (isotype) is joined to the variable region 
by DNA recombination. This allows keeping the specificity unchanged while adjusting the 
functional properties (see next chapter for functional properties of isotypes) [1]. As a final step 
of maturation to become an antibody-producing cell, the cytoplasmic tail and transmembrane 
region of the BCR is removed by alternative mRNA processing resulting in the secreted form of 
the BCR, now called antibody. This process enables a B cell to produce secreted and membrane-
bound Ig at the same time allowing it to still be responsive to BCR stimuli and adapt the antibody 
production depending on the needs of the immune system [3]. Besides immediate antibody 
production following a successful germinal center reaction, few cells become long-lived plasma 
cells or quiescent long-lived memory B cells. Upon reencounter of a pathogen, such a memory 
B cell can again enter the germinal center reaction, undergo further SHM, isotype switching 
and differentiation in memory- or plasma cells. This secondary B cell response happens much 
faster than the primary response because of pre-existing high-affinity antibodies and memory 
B cells (in addition to enhanced T cell responses, not discussed here). Both germinal-center 
derived B cell populations from the primary response contribute to accelerate the secondary 
response. Bone-marrow resident, germinal-center derived long-lived plasma cells are providing 
enhanced protection by continuously secreting antibodies and long-lived memory B cells reside 
in or recirculate between the spleen and secondary lymphoid organs where, upon encounter of 
their cognate antigen and stimulation by helper T cells, they mount a potent secondary immune 
response [3].  
1.2.5 Classification and function of human antibody isotypes
Based on major structural differences, five isotype classes (IgG, IgM, IgA, IgE and IgD) can 
be distinguished. IgG can be further subdivided in the subclasses IgG1-4 and IgA in IgA1 and 
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IgA2 [1] (table 1.2). IgM is the first isotype produced during a primary immune response. 
It comprises the major pool of germline-encoded “natural antibodies” which have a limited 
affinity but broad antigen specificity [30]. Pentamerization (or sometimes hexamerization) by 
means of association with an additional polypeptide, the J chain produced by antigen secreting 
cells, allows increasing the avidity for repetitive structures. This reflects the essential role of 
IgM in the first line of defense against invading microbes by activation of the complement 
system [45] and for tissue homeostasis by the clearance of apoptotic cells [46]. IgA is found in 
body fluids such as the mucous, saliva, teers and breast milk but also in serum [47]. In order to 
enter mucosal secretions, IgA needs to dimerize or oligomerize with the J chain, which allows 
its transfer across mucosal epithelial cells by means of the polymeric immunoglobulin receptor 
[48, 49]. Mucosal IgA neutralizes pathogens and toxins without the initiation of an inflammatory 
response due to its limited ability to activate the complement system and plays an important role 
in establishing a mutual relationship with commensal bacteria [50-53]. Both IgA1 and IgA2 are 
found in the mucosa whereas in serum IgA is mainly restricted to monomeric IgA1 [53, 54]. 
Circulating IgA can bind to several receptors including FcaRI expressed on various innate 
immune cells but the functional consequence is poorly understood [53]. IgA concentration in 
colostrum exceeds 12 mg/ml reflecting its important role in protecting newborns via the breast 
milk against various microorganisms [47, 55]. IgE is mainly known for its protective effect 
against helminths as well as its pathophysiological significance in type I hypersensitivity and 
allergy [56]. IgE effector functions are mediated via the high-affinity IgE-Fc receptor (FceRI) 
expressed on mast cells and basophils as well as human macrophages and DCs [57]. Antigen 
induced FceRI cross-linking on mast cells and basophils induces the release of inflammatory 
mediators such as histamins, proteases and heparin in addition to the production of cytokines 
and chemokines [58]. FceRI expression on antigen presenting cells was suggested to influence 
antigen presentation to, and phenotypic development of T cells [57]. Cell-surface bound IgD 
constitutes together with IgM the initial B cell receptor of a mature B cell and its function as 
secreted antibody is still enigmatic. IgD class-switched plasmacytoid B cells were found in the 
upper respiratory mucosa and secreted IgD bound to myeloid cells via an unknown receptor. 
It was therefore suggested that IgD plays a role in enhancing immunity to airborne pathogens 
[59]. The last antibody class, IgG, is of particular importance for this work and will be discussed 
in more detail below. 
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Class IgD IgM IgG IgA IgE
Subclass IgG1 IgG2 IgG3 IgG4 IgA1 IgA2
Molecular weight (kDa) 188 970 (pentamer) 146 146 165 146
160
(monomer)
160
(monomer) 184
Serum concentration 
(mean adult mg/ml) 0.03 1.5 9 3 1 0.5 3 0.5 5 x 10
-5
Half-life in serum (days) 3 10 21 20 7 to 21* 21 6 6 2
Palcental transfer +++ + + to +++* ++
Mucosal transfer + +++ +++
* depends on allotype.
IgE 
IgG1 IgG2 IgG3 IgG4
IgD IgM
IgA1 dimer
IgA2 monomer
Table 1.2: Basic characteristics of human antibody isotypes 
Adapted from [3, 31, 49, 60].
Figure 1.2 Structure and function of human antibody isotypes. 
The structure of all human antibody isotypes is shown. IgM and IgA represented in their most 
frequently occurring polymeric form in association with the J chain (grey circle). Disulfide bonds are 
indicated as dotted lines. The number of disulfide bonds of IgG3 depends on the allotype. Modified 
from [1, 31, 47, 61-64].
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1.3 Immunoglobulin G
1.3.1 The structure and function of human IgG subclasses
IgG is the prototypic antibody isotype and the predominant antibody in serum. IgG HCs are 
encoded by four closely related genes, the translation of which results in the isotypes IgG1, 
IgG2, IgG3 and IgG4 (figure 1.2). The numbering of the isotypes is not based on their genomic 
location but on relative abundance in serum (table 1.2) [65, 66]. Although 90% homologous in 
amino acid sequence, differences in the regions containing the binding sites for mediators of 
cellular and humoral effector mechanisms result in important functional differences. One area 
of high diversity is the hinge region which contains the inter-HC disulfide bonds. The length of 
the hinge, its amino acid composition and the amount of disulfide bonds varies between the four 
subclasses and results in major differences in Fab arm flexibility. IgG3 is most flexible followed 
by IgG1, IgG4 and IgG2 [67]. Besides the hinge region, the amino acid composition of the 
CH2 domain is the most diverse IgG region [31]. IgG mediated complement activation (C1q 
binding) is strongly influenced by hinge and CH2 structure resulting in IgG3 being the most 
potent complement activator followed by IgG1. IgG2 only weakly binds C1q and IgG4 does 
not activate the complement system [31]. The influence of the IgG subclass on FcgR binding is 
summarized in figure 1.5. 
1.3.2 IgG glycosylation
An estimated 50 % of the proteins in our body carry glycans making glycosylation the most 
frequently occurring post-translational modification (PTM). In addition, the large variety of 
different combinations of sugars results in glycosylation also being the most complex PTM 
[68]. The glycosylation of IgG is unique among all antibody classes because it consists only 
of a single, highly conserved asparagine-linked glycan (N-glycan) in the CH2 domain of the 
HC of all subclasses [33]. In addition 15 to 20 % of circulating IgG contain N-glycans in the 
variable regions of HC and/or LC due to the generation of glycosylation sites during somatic 
mutation of antigen-binding regions [69-72]. As suggested by their location, Fab glycans 
influence the antigen binding property of antibodies [72]. For reasons of completeness it has 
to be mentioned that a rarely glycosylated, non-classical N-glycosylation site has also been 
observed in the CH1 domain of IgG [73]. In contrast to these additional glycosylations, the 
Fc glycan is indispensable for IgG to be successfully produced. During protein translation a 
pre-formed lipid-linked glycan is transferred and covalently attached to asparagine at position 
297 in the lumen of the endoplasmatic reticulum (ER). This initial glycan is composed of two 
N-acetylglucosamines (GlcNAc) followed by branched mannose (Man) residues. Its structure 
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is highly conserved in eukaryotes and serves as an important mechanism for protein folding and 
quality control of proteins carrying N-glycans [74]. If successfully produced and folded, the 
IgG polypeptide is transferred from the ER to the Golgi network where glycosyl-hydrolases and 
-transferases can modify the core glycan leading to such diverse and highly complex glycans 
as seen in the IgG-Fc. The monosaccharide composition of the glycan is impacted by the 
amino acid sequence as well as glycan modifying enzyme- and substrate availability [75]. The 
presence of glycosylhydrolases and glycosyltransferases in the Golgi is regulated at the level of 
transcription and location within the secretory pathway [76]. Peptide-glycan interactions and the 
three-dimensional structure of the Fc are thought to limit the glycan variability and the extent of 
galactosylation and sialylation by limiting the accessibility of the glycan to glycosyltransferases 
[75, 77]. A total of more than 30 different glycan structures is found in the IgG-Fc pool [33, 78]. 
Compared to the Fab glycans, reduced bisecting GlcNAc, less galactose and less sialylation 
is found on the Fc glycans [71, 77]. The restricted glycan diversity may be essential to enable 
directed IgG-Fc glycan modifications and use them for shaping antibody functionality. How 
and which immunological factors such as cytokines influence antibody glycosylation is yet 
to be defined but much progress has been made in understanding the structural and functional 
consequences of the presence or absence of different sugar moieties on the IgG-Fc carbohydrate. 
In addition to the oligosaccharide core, more than 95 % of the bi-antennary complex type 
structure of the final IgG glycan carries a N- acetylglucosamine on both arms [78, 79] and 85 
% are fucosylated [80]. In contrast, the presence of galactose is less homogenous with 40 % of 
glycans carrying one galactose (G1 glycan) and the frequency of non-galactosylated (G0) or 
bi-galactosylated glycans (G2) ranging between 20 and 40 % depending on age and gender [79, 
81]. Additional heterogeneity is conferred by the presence of a bisecting N-acetylglucosamine 
present on approximately 10 to 15 % of total IgG-Fc glycans [82]. Based on the structure of 
the glycan, the conformation of the IgG-Fc homodimer in the binding interface to Fc-receptors 
and the complement protein C1q (CH2 domain) changes from an open (maximal C2-C2 domain 
distance) to a closed conformation (minimal C2-C2 domain distance) [83, 84]. Analysis of 
crystal structures revealed that removal of terminal galactose and N-acetylglucosamine 
residues favors a closed conformation which impacts thermal stability and accessibility for IgG 
binding molecules [84-86]. The most distal sugar on the glycan is sialic acid (neuraminic acid, 
Neu5Ac). Around 10 % of glycans carry sialic acid on one arm and bi-sialylated glycans are 
found only in trace amounts. The linkage of sialic acid to the penultimate galactose is found 
in either α2-3 or α2-6 confirmation with a strong preference for the latter [33]. Galactose is 
added mainly to the 1-6 arm of the glycan, whereas sialic acid is almost exclusively found on 
the 1-3 arm [77]. While the 1-6 arm bias of galactose may be largely explained by accessibility 
[77] the 1-3 arm specific addition of sialic acid by human sialyltransferase is retained even in 
vitro using the released Fc glycan, substrate and recombinant human sialyltransferase arguing 
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for an enzyme-intrinsic bias [87]. The opposing glycan arm-bias of galactose and sialic acid 
provides a rationale for the inefficient addition of sialic acid. The functional consequences of 
the different glycan structures will be discussed in chapter 1.3.4)
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1.3.3 IgG effector functions 
Immunoglobulin G (IgG) represents 75 % of the immunoglobulins in serum reflecting 
its role in defending us against bacteria and viruses which have penetrated beyond 
epithelial and mucosal barriers [3]. Like for other antibodies, the Fab region of IgG can 
directly neutralize pathogens. Additionally, IgG can be bound by receptors specific for the 
antibody’s Fc region (FcgRs), which allows FcgR-expressing cells to use the specificity 
of the Fab and combine it with their functional capabilities. Examples therefore are 
antibody-dependent cell-mediated phagocytosis (ADCP) and antibody-dependent cell-
mediated cytotoxicity (ADCC) (figure 1.4). Also, IgG (IgG1 and IgG3) and IgM are the 
most potent antibodies in terms of activation of the complement system. 
1.3.3.1 Cellular effector functions of IgG: The role of FcgRs 
Receptors binding the Fc region of IgG, Fcg-Receptors (FcgRs), are crucial for the functionality 
of antibodies. They contribute to clearance of pathogens and virus- or tumor-transformed cells 
by facilitating their uptake, inactivation and processing for antigen presentation. 
Figure 1.3 Structure of the IgG-Fc N-glycan
An IgG antibody containing two glycan residues and a fully processed N-glycan, galactosylated, 
sialylated and containing a bisecting N-acetylglucosamine is shown. Modified from [88].
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Traditionally, these receptors are divided into two groups based on their inhibitory or activating 
function (figure 1.5) reflected by the presence of either an immunoreceptor tyrosin-based 
inhibitory (ITIM) or -activation motif (ITAM) sequences in their intracellular domain or their 
signaling adaptor molecules. All classical FcgRs (FcgRI, FcgRII-A, -B, -C, FcgRIII-A, -B) bind 
to the upper CH2 and hinge region of IgG [89-93]. The receptor`s affinity for IgG determines 
if the antibodies bind in a monomeric form and cells expressing the respective FcgR are 
therefore constantly associated with surface-bound antibodies. Alternatively, formation of an 
immune complex is required to allow FcgR binding. Innate immune cells such as monocytes, 
macrophages and DCs express several FcgRs on their cell surface and can co-express activating 
FcgRs (FcgRI, FcgRIIA and FcgRIIIA) with the inhibitory FcgRIIB. Relative expression levels 
of activating versus inhibitory receptors have been shown to influence the response towards 
Figure 1.4 Effector functions of IgG
Schematic depiction of the main IgG effector functions. ADCP (Antibody-dependent cell-
mediated phagocytosis); ADCC (Antibody-dependent cell-mediated cytotoxicity); CDC 
(Complement-dependent cytotoxicity). Modified from [3].
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immune complexes and set the threshold for DC activation [94]. FcgRIIA is particularly 
important for ADCP mediating the internalization of immune complexes for antigen processing, 
presentation and degradation [95, 96]. 
Similarly to its function on myeloid cells, FcgRIIB negatively regulates signaling in B cells 
via the BCR resulting in decreased antigen-induced proliferation and antibody production [97, 
98]. Its expression on plasma cells controls their persistence in the bone marrow [99] and the 
deletion of FcgRIIB was found to result in increased frequencies of auto-reactive plasma cells 
in transgenic mouse model expressing a DNA-specific immunoglobulin heavy chains [100]. 
FcgRIIIA is the main FcgR found on natural killer (NK) cells where it is essential for the lysis 
of tumor- or virus-transformed cells by ADCC. Through FcgRIIIA, NK cells bind to antibodies 
bound to the surface of a pathogen or transformed cell and lyse the target by releasing pre-
formed cytotoxic granules [3, 101]. About 20% of individuals additionally express FcgRIIC on 
NK cells which may also have important implications for NK cell functions [102]. 
Fc-receptors also contribute to the exceptionally long half-life of IgG antibodies (see table 1.2). 
The neonatal FcR (FcRn) cycles between the cell surface and acidic endosomal compartments 
where low pH allows its binding to internalized IgG. FcRn-IgG complexes are then transported 
back to the cell surface and physiological pH leads to the dissociation of the FcRn-IgG complex 
and IgG’s release back to circulation [103]. This process not only increases the half-life of IgG 
up to five fold but also allows trans-epithelial transport [104, 105]. 
1.3.3.2 Humoral effector functions of IgG: The complement pathway
The complement system is traditionally seen as an innate defense mechanism against invading 
pathogens. Accordingly, initiators of the complement system such as mannose-binding lectin 
(MBL), ficolins and C1q are potent pattern-recognition molecules. Upon target surface binding 
of MBL, ficolins or C1q, associated serine proteases get activated and cleave C4 into C4a and 
C4b. This in turn leads to the exposure of a thioester group in C4b resulting in its covalent 
surface deposition. Thereby, C4b turns into an active protease and cleaves C2 into C2a and 
C2b. C4b and C2b form together the C3 convertase C4b2b. C3 is the central molecule for 
all complement pathways. Again, if C3 is cleaved by its convertase, a reactive thioester is 
exposed leading to the covalent binding of C3b to amines and carbohydrates on target surfaces. 
In the classical and lectin pathway, C4b, C2b and C3b form the C5 convertase, which in turn 
associates with C6 and C7 and inserts into the surface of the target cell. Finally, this complex 
interacts with C8 and several units of C9 to form the membrane attack complex, a lytic pore 
in the cell membrane [3, 108]. In addition to this lytic process, C3b opsonizes targeted cells 
15
Introduction
for phagocytosis via receptors on macrophages and DCs (such as CR1, 3 and 4) [108]. It 
Reference: K. Smith et al., Nature rev immunology 2010
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Name FcgRI FcgRIIA FcgRIIC FcgRIIIA FcgRIIIB FcgRIIB
CD CD64 CD32A CD32C CD16A CD16B CD32B
Expression
Lymphoid not expressed not expressed NK cells NK cells not expressed B cells, plasma cells
Myeloid Monocytes, DCs, macrophages
Monocytes, DCs, 
macrophages not expressed
Monocyte, DC 
macrophage not expressed
Monocytes, DCs, 
macrophages
Granulocyte Neutrophils, eosinophils Neutrophils not expressed not expressed
Neutrophils, 
mast cells, 
eosinophils
Neutrophils, baso-
phils, mast cells
IgG binding 
affi nity
FcgR allele - H131 R131 Q13 stop13 V158 F158 - I232 T232
IgG1 6x107 5x106 3x106 1x105 - 2x105 1x105 2x105 1x105 ND
IgG2 - 5x105 1x105 2x104 - 7x104 3x104 - 2x104 ND
IgG3 6x107 9x105 9x105 2x105 - 1x107 8x106 1x106 2x105 ND
IgG4 3x107 2x105 2x105 2x105 - 2x105 2x105 - 2x105 ND
also 
lowers the threshold for B cell stimulation (via CR2), facilitating antigen presentation and 
initiation of an adaptive immune response [108, 109]. This process is further amplified by 
anaphylatoxins C3a and C5a, the small proteolytic fragments of C3 and C5, which act as potent 
chemoattractants for antigen presenting cells and trigger proinflammatory signaling via binding 
to C3aR, C5aR and C5L2 [110, 111]. The importance of the complement system for the defense 
against microbes is demonstrated by C3 deficiency, which leads to recurrent and life-threatening 
bacterial infections [112]. In addition, complement is involved in the removal of apoptotic 
cells and deficiency in components of the classical complement pathway, in particular C1q, is 
associated with autoimmunity [113]. This highlights the importance of the complement system 
not only for the defense of the body but also for its homeostasis.   
Depending on the isotype, IgG antibodies are potent initiators of the complement cascade. 
Three ways of IgG-mediated complement activation have been described. First, antigen-bound 
IgG is a high-affinity binding partner for C1q [83, 114]. Second, mannose-binding lectin (MBL) 
Figure 1.5 Human FcgRs
Schematic depiction of human FcgRs g-chains and the major signaling adaptor molecule for 
FcgRI and FcgRIIIA, the common gamma chain dimer (g2). Immune-tyrosine based activation 
(ITAM) - or inhibition (ITIM) sequences in the intracellular domain or adaptor molecule are 
indicated. FcgR expression pattern and binding affinity of allelic FcgR variants to IgG isotypes 
is shown [106, 107]. FcgRIIC is only expressed by 20 % of individuals [102]. The three 
known allelic variants of FcgRIIIB are not indicated as they have shown no differences in FcgR 
binding properties. Modified from [106, 107].
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can bind IgG containing non-galactosylated IgG-Fc glycans [115, 116]. Third, spontaneously 
activated C3b has a certain affinity for IgG and forms C3b2-IgG complexes [117-119]. The 
C1q-dependent pathway is presumably most important for IgG function and best understood. 
It enables IgG-mediated lysis of both microbes and cells by formation of the membrane attack 
complex, a process called complement-dependent cytotoxicity (CDC) (figure 1.6). 
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1.3.4 Regulation of IgG effector functions by the IgG-Fc glycan
The IgG-Fc glycan is located in the CH2 region in proximity to the FcgR and C1q binding sites 
suggesting its involvement in their intermolecular interaction [93, 114]. In accordance with 
that, absence of the IgG-Fc N-glycan results in the abrogation of effector-FcgR binding [120] as 
well as C1q binding [86, 121, 122]. In contrast, the binding of IgG to FcRn and therefore serum 
half-live was found to be hardly affected by the presence or absence of the IgG-Fc N-glycan. 
This is likely explained by the distinct position of the FcRn binding site located between the 
CH2 and CH3 domain of IgG-Fc [123, 124]. 
From the three variable sugar residues galactose, sialic acid and fucose, the latter has the most 
pronounced effect on antibody functionality. Its presence largely reduces the affinity of IgG 
for FcgRIIIA [92] and therefore NK cell mediated ADCC. This finding is currently assessed 
for its clinical applicability with at least 12 de-fucosylated antibodies being evaluated as anti-
cancer therapeutics in clinical trials [125] and mogamulizumab (non-fucosylated humanized 
mAb recognizing CCR4) already approved for relapsed or refractory CCR-4-positive adult T 
cell leukemia-lymphoma in Japan [126]. 
The reduced frequency of galactose in the IgG-Fc glycan during inflammation due to 
autoimmunity or infection was reported in numerous studies [78, 127-131]. However, very 
little evidence exists for a functional consequence. Agalactosylated IgG was found to depend 
on FcgRs for in vivo functionality [116] although in the absence of galactose, IgG gains the 
Figure 1.6 The classical complement pathway. 
Binding of an antibody to its cognate antigen induces the assembly of C1 which in turn results in the 
induction of the complement cascade culminating in the insertion of the membrane attack complex in 
the cell membrane and lysis of the cell. Modified from [1, 3] 
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ability to interact with mannose-binding lectin (MBL) [115] and could therefore activate the 
complement system via the lectin pathway [115, 116]. Also, the presence of galactose favors 
C1q binding [116] but suppresses C5aR signaling via dectin-1 and FcgRIIB cross-linking [132]. 
An additional important aspect to consider when looking at the functional impact of galactose 
is that it provides the basis for the addition of sialic acid, the most distal sugar moiety on the 
IgG-Fc glycan. But again, very little is known about the significance of sialic acid for antibody 
functionality. It was suggested that IgG-Fc sialylation may reduce both activating and inhibitory 
FcgR [133] binding as well as ADCC [134], but further investigations, in particular for human 
antibodies and receptors have to be carried out to confirm that effect. Conflicting results exist 
whether sialylated IgG gains the ability to bind the adhesion and antigen capture molecule DC-
SIGN or its murine ortholog SIGN-R1 [135-138]. The most convincing data about a functional 
role of sialic acid were found for its role in mediating the anti-inflammatory effect of pooled 
human antibodies [133, 139]. This will be discussed in more detail in chapter 1.3.6.2. 
1.3.5 Anti-inflammatory IgG: intravenous immunoglobulin (IVIG)
In 1981, Paul Imbach made a surprising discovery, which should turn out to become one of the 
most efficient and best-tolerated treatments for several human autoimmune diseases. A patient 
suffering from both hypogammaglobulinemia and immune thrombocytopenia (ITP) received 
intravenous injections of high-dose polyclonal antibodies purified and pooled from numerous 
serum donors as immunoglobulin replacement therapy to complement his IgG deficiency. 
Unexpectedly, not only the serum-immunoglobulin levels increased but also the number of 
platelets [140, 141]. This led to the idea that IgG may have anti-inflammatory properties in 
addition to the well-established pro-inflammatory functions. Since then successful clinical 
studies prompted the approval of IVIG in the autoimmune diseases ITP, Kawasaki`s disease, 
chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy 
(MMN) [142]. Furthermore, IVIG has applications in many other neuromuscular, hematologic or 
dermatologic disorders. Examples are Guillain-Barré syndrome, myasthenia gravis, relapsing-
remitting multiple sclerosis, graft-versus-host disease and pemphigus vulgaris [142]. 
1.3.5.1 Properties of IVIG and clinical regimen
The purification of IgG from pooled serum for immunoglobulin replacement therapy has been 
developed in the 1940 and was based on cold ethanol preparation. With a few adaptations, this 
is still today the core method except for one company using caprylate precipitation [143]. The 
IgG subclass distribution in IVIG reflects what is found in healthy human serum being 68 % 
IgG1, 29 % IgG2, 4-8 % IgG3 and 1 % IgG4 [144, 145]. Besides, small amounts of IgA and 
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IgM are also present [143]. IVIG is prepared as physiologic salt solution, the pH varies between 
4 and 7.2 depending on the preparation and in order to avoid aggregates, sugars (either glucose, 
sorbitol, mannose or maltose) are added in most preparations [143]. IgG concentration in the 
infusion solution is usually between 50 and 100 g/l [143]. The treatment regimen depends on 
the disease and the individual patient. A standard application for the treatment of autoimmunity 
would be 2 g/kg initially and 1 g/kg maintenance infusion every 3-6 weeks [145, 146]. 
1.3.6.2 The anti-inflammatory mechanisms of IVIG
Despite IVIG`s clinical efficacy in a wide range of autoimmune diseases, it has not been 
possible to find a uniform mechanism of action yet, suggesting that various aspects of IgG play 
a role. Possible mechanisms identified so far (table 1.3) can be divided in two groups based 
on their association with the functional components of IgG, Fab or Fc. The large variety of 
antigen specificities contained within the IVIG preparation and the high dose given to patients 
potentially allows rare antigen specificities to block, remove and neutralize components of the 
immune system as well as environmental factors such as microbes. Exemplary mechanisms are 
interference of cell homing and interaction by blocking of integrins [147], immune modulation 
by blocking of cytokines [148-150], neutralization of pathogenic autoantibodies by anti-
idiotype antibodies [151, 152] and modulation of host-bacteria (commensals and pathogens) 
interaction by anti-carbohydrate antibodies [153]. In addition, the constant region of F(ab`)2 
fragments was shown to neutralize anaphylatoxins C3a and C5a by physical association [154]. 
Unlike F(ab`)2 mediated anti-inflammatory properties which were so far only demonstrated 
in vitro or in animal models, a clinical trial showed efficacy of Fc fragments in ITP [155]. 
Numerous follow-up studies investigated the protective mechanism of Fc. Obtained results 
include FcgR blocking [156], modulation of FcgR expression [157] and signaling [158], 
increased autoantibody clearance by FcRn saturation [159], suppression of immunoglobulin 
production [160], modulation of antigen presenting cell activation by induction of inhibitory 
FcgRIIB [161] as well as blockade of complement proteins [162]. Interference with the function 
of antigen presenting cells [161, 163] can shape adaptive T and B cell responses. Similarly, 
peptide epitopes contained within the constant regions of the IgG heavy chain were shown to be 
recognized by regulatory T cells which may in turn suppress autoreactive T cells [164]. Because 
an extremely high dose of IVIG is required for its efficacy (1-2 g per kg), it was speculated 
that the beneficial effect may be mediated by a small sub-fraction of IVIG. Jeffrey Ravetch 
and colleagues identified the presence of the IgG-Fc glycan to be essential [133]. In particular, 
the most terminal sugar moiety, a2-6 linked sialic acid, was found to be the anti-inflammatory 
mediator of IVIG in the K/N experimental arthritis model [133, 165]. Collectively, studies in 
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murine models and human autoimmune diseases suggest that the IgG-Fc portion is sufficient 
to mediate the anti-inflammatory action of IVIG [133, 155] possibly via sialic acid [133, 139, 
165-167] and FcgRIIB [139, 157, 158]. In addition, F(ab`)2 mediated immune-modulation may 
play a role by blocking of inflammatory mediators [147, 149]. 
Mechanism Reference
Anti-idiotypic antibodies [151] [152]
Modulation of immunomodulatory molecules (cytokines, 
chemokines, receptors, adhesion molecules) [147-150, 168-172]
Neutralization of pathogens and superantigens [153, 173]
Interference with FcgR signaling and expression [139, 156, 157, 174-176]
Interaction and signaling via DC-SIGN (SIGN-R1) [136, 161]
Modulation of complement activity [154, 177, 178]
Modulation of maturation and function of DCs [163]
Blockade of FcRn [159]
Regulatory T cell activation via “Tregitopes” [164]
Suppression of immunoglobulin production by B cells [160]
Improvement of steroid signaling [179]
1.4 Chronic inflammatory demyelinating polyneuropathy (CIDP) 
1.4.1 Clinical manifestation of CIDP
CIDP is an acquired autoimmune disease of the peripheral nervous system and represents the 
most common chronic autoimmune neuropathy with a prevalence between 1.9 and 8.9 per 100 
000 individuals [180, 181]. The disease usually develops insidious over the course of weeks to 
years and is characterized by progressive, symmetric motor and sensory deficits in the limbs as 
well as paresthesia and impaired balance with large inter-patient variation as to the involvement 
of the individual characteristics [181-185]. In its most severe form CIDP can lead to complete 
immobilization and eventually death [186, 187]. CIDP is more common in elderly individuals, 
but onset can occur from early childhood on throughout life with males being more often 
affected than females [182]. The disease course can be chronic progressive or contain relapses 
with various degrees of remaining disability [182, 187]. 
Table 1.3 Suggested anti-inflammatory mechanisms of IVIG
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1.4.2 CIDP treatment and disease pathology
At least two thirds of patients with CIDP respond to immunotherapy [181, 188]. Randomized 
controlled clinical trials showed an overall similar efficacy of corticosteroids [189], IVIG [190-192] and plasma exchange [193-195]. Steriods (prednisolone) and IVIG are considered first-line 
treatments but the exact treatment regimen has to be individually tailored based on the disease 
severity, age and general health status [196]. If patients do not respond, immunosuppressants 
and CD20-monoclonal antibody mediated B cell depletion is sometimes used but no controlled 
clinical trial has shown usefulness so far [188, 196]. Treatment success was found to correlate 
with age of onset [197] and the involvement of proximal or distal muscle weakness [198]. 
Juvenile CIDP patients are likely to respond well to treatment and achieve complete recovery 
whereas most elderly patients do not show complete recovery [197]. 
CIDP is regarded as an autoimmune disease and disease pathology is thought to involve 
autoantibodies, T cells, macrophages and complement. The main immune cells found in 
active lesions are macrophages and few T cells [181, 183, 186]. Successful treatment by 
plasmapheresis, which depletes the blood of soluble factors such as cytokines, chemokines 
and antibodies, suggests that humoral immune mediators play an important role [181]. The 
cerebrospinal fluid (CSF) of CIDP patients contains increased overall protein concentration 
[199] and elevated chemokine and cytokine levels [172, 199-202]. In addition, deposits of 
antibodies and complement on the surface of myelin sheaths [203] and transferability of 
demyelination by the intraneural injection of serum or IgG from CIDP patients into rodents [204] 
supports the relevance of antibodies for disease pathology. Both complement and macrophages 
could contribute to the neuropathology of antibodies but also antibodies on their own could be 
disease-relevant by modulation of signaling via receptors and soluble mediators [205]. 
Despite increasing evidence for antibodies as mediators of immunopathology in CIDP, the 
nature of a potential autoantigen is still largely elusive. Small subgroups of patients were 
found to have antibodies binding to neurofascin [206] or contactin-1 [207] and myelin-reactive 
antibodies are only present in rare cases [208]. In addition, higher than normal titers of b-tubulin 
reactive antibodies are found in less than half of CIDP patients but their significance for disease 
pathology remains unknown [209, 210]. The diversity of CIDP disease pathology may also be 
the result of several target autoantigens involved and identification of such would have a great 
potential to differentiate CIDP subtypes and optimize the treatment. 
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1.5  Experimental autoimmune encephalomyelitis (EAE) - T cell mediated neuro-
inflammation of the central nervous system
 
1.5.1 History of EAE
Louis Pasteur used repeated injections of dried spinal cord of rabies infected rabbits as post-
exposure vaccine [211]. Despite its clinical success against rabies, temporal neurologic 
impairments such as facial palsy or paresis of limbs were frequently occurring side-effects [212]. 
In its most severe form, progressive paralysis started from the lower extremities, ascended to the 
upper limbs and neck and finally affected breathing and swallowing culminating in death [213-
215]. In the beginning, the neurological impairments were attributed to the virus until it was 
found that repeated injections of rhesus macaques with uninfected rabbit brain also resulted in 
impaired movement and myelin degeneration [216, 217]. The first hint that the immune system 
may play a role originated from the observation that brain-specific antibody titers correlated 
with the appearance of paralysis [218]. A logic consequence was that stimulation of the immune 
system by use of an adjuvant should exacerbate the pathogenicity of brain injections. This 
was the starting point for the development of experimental autoimmune encephalomyelitis 
(EAE), the immunization of animals with brain extracts emulsified in oil containing heat-killed 
Mycobacterium tuberculosis (the so-called complete Freund’s adjuvant, CFA) [212]. Although 
details in the disease phenotype vary, the organ-specific neurological phenotype of EAE was 
replicated in numerous animals including pigs, rabbits, goats, rats, dogs, chicken and mice 
[212]. Efforts to identify the antigenic components led to a stepwise simplification of the model 
until only a single antigenic peptide replaced the whole brain lysate. Although antibodies were 
the first indicators of a role for the immune system in disease pathology, the use of peptides 
resulted in a T cell dependent model of autoimmune neuroinflammation [219, 220] with a 
critical involvement of many other cell types and inflammatory mediators strongly depending 
on the species, strain and epitope used [221, 222]. The most commonly used peptides for 
EAE in mice are derived from either myelin basic prvotein (MBP) or myelin oligodendrocyte 
glycoprotein (MOG). The next chapter briefly introduces the distinctive features of T cells 
as well as their subsets and effector mechanisms before going into further details about the 
pathology of EAE. 
1.5.2 T cells: Basic properties and comparison to B cells
T cells are, besides B cells, the second cellular component of the adaptive immune system. Both 
subsets develop from a common pluripotent bone-marrow derived lymphocyte progenitor cell 
but whereas B cells undergo a large part of their development in the bone marrow, early T cell 
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progenitors home to the thymus. T cells have an antigen receptor composed of an alpha and beta 
chain and accessory signaling molecules. Also the basic principles of antigen receptor repertoire 
development by somatic gene segment rearrangement, V(D)J recombination, as well as positive 
and negative selection (although involving different tissues and cell types) are very similar 
among B and T cells. However, there are some important differences. First, additional diversity 
by somatic hypermutation does not exist in T cells. Second, T cells do not recognize native 
antigens but peptides presented by “major histocompatibility complex” (MHC) molecules of 
other cells. Third, the TCR remains membrane-bound and T cells themselves are the cellular 
mediators of effector functions such as target cell lysis and stimulation of innate and adaptive 
immune responses by the secretion of cytokines [3]. The next chapter briefly summarizes the 
different subsets of T cells and their respective functions in the immune system.
1.5.2.1 T cell subsets and their effector functions
Naïve mature T cells can be divided in two subsets based on their expression of either CD4 or 
CD8. These TCR co-receptors are essential for the interaction with antigen-bound MHC. They 
functionally restrict CD4 T cells to recognize peptides in the context of MHC class II (MHC-II) 
and CD8 T cells in the context of  MHC class I (MHC-I) [223]. MHC-I is expressed on almost all 
nucleated cells and presents peptides derived from intracellular origin. Intracellular (cytosolic) 
proteins, host or pathogen-derived, are degraded by the proteasome, loaded on MHC-I in the ER 
and finally presented on the cell surface [3]. This mechanism is of particular importance for the 
immune system to detect virally transformed cells by the recognition of virus-derived peptides 
via CD8+ T cells [3]. Activation of CD8+ T cells leads to cytokine production and lysis of the 
target cell. This subset is therefore called cytotoxic T lymphocyte (CTL). MHC-II molecules 
are mainly expressed on so-called professional antigen presenting cells (e.g. DCs) as well as 
B cells and present peptides derived from extracellular proteins. Endocytic vesicles fuse with 
specialized MHC-II loading compartments and the peptide-associated MHC-II molecules are 
transported to the cell surface. Recognition of the cognate antigen by a CD4+ T cell (also called 
helper T cell) usually does not result in lysis of the presenting cell but rather in stimulation 
of its ability to destroy the phagocytosed microbe. In addition, the secretion of cytokines and 
chemokines recruits other immune cells and stimulates the capacity of antigen presenting cells 
to amplify the primary immune response and initiate a secondary immune response. Based on 
their expression of specific transcription factors and secretion of cytokines, several subsets of T 
cells can be distinguished [224]. The best-characterized subsets are shown in table 1.4. CD4+ T 
cells also have an essential function during the induction and recall of antigen-specific antibody 
responses by the recognition of pathogen-derived peptides on MHC-II molecules on the surface 
of B cells. T - B cell interaction in the lymph node results in the migration of B cells into the 
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primary follicle where, upon antigen recognition, they start to proliferate and initiate a germinal 
center reaction [3]. Again, T cells are indispensable. The production of IL-21 and CD40 - 
CD40-ligand interaction with germinal-center B cells is essential to maintain the germinal 
center reaction as well as differentiation of high affinity non-self reactive B cells into long lived 
memory and plasma cells by a yet to be defined mechanism [225, 226]. A specialized subset of 
CD4+ T cells expressing the transcription factor FoxP3 has important functions in regulating 
peripheral T cell tolerance by inhibition of T cell activation and modulation of their effector 
functions [227]. In addition, gd T cells and mainly lipid-recognizing natural killer T (NKT) 
cells exist which will not be discussed here. Both CD4+ and CD8+ T cells can differentiate into 
memory T cells and provide superior protection upon a secondary infection [3]. 
Th cell 
subset
Differentiation 
stimulated by
Lineage-defi ning 
transcription factors
Signature 
cytokines Responsive cells Major fucntions
Th1 IL-12, IL-27 STAT4, T-bet
IFN-g, TNF-a, 
TNF-b, IL-3, 
GM-CSF
DCs, macrophag-
es, neutrophils, 
NK cells, B cells
Cell-mediated immunity 
(defense against intracellular 
bacteria & viruses)
Th2 IL-4, IL-25 STAT6, GATA3
IL-3, IL-4, IL-5, 
IL-9, IL-10, IL-
13, GM-CSF
DCs, macrophag-
es, eosinophils, 
mast cells, baso-
phils, B cells
Humoral immunity (defense 
against extracellular para-
sites such as helminths), 
mucosal immunity, allergy, 
asthma
Th17 TGF-b, IL-6, IL-21
STAT3, ROR-a, 
ROR-gt
IL-17A, IL-17F, 
IL-21, IL-22
Neutrophils, 
macrophages, 
endothelial cells, 
epithelial cells
Cell-mediated infl ammation, 
defense against extracellular 
pathogens and fungi, auto-
immune diseases
Treg TGF-b Foxp3 TGF-b, IL-10 DCs, macro-phages, B cells
Immunoregulation (periph-
eral tolerance)
Tfh IL-6, IL-21 STAT3, Bcl-6 IL-4, IL-10, IL-21
Germinal center B 
cells
B cell maturation, regulation 
of peripheral tolerace in the 
germinal center
References: {Leung, 2010 #431}{Nurieva, 2010 #433}{Wan, 2010 #434}{Abbas, 2007 #244}
1.5.3 Disease pathology of MOG35-55 peptide induced EAE in C57BL/6 mice
EAE is induced in C57BL/6 mice (B6 mice) by subcutaneous immunization with the 
immunodominant MOG35-55 peptide emulsified in CFA [228]. This results in a continuous 
release of adjuvant and peptide. In addition, mice receive pertussis toxin, which is thought 
to facilitate the development of clinical symptoms by aiding to open the blood-brain barrier 
and modulation of APCs and T cells [229, 230]. MOG protein expression is largely restricted 
to the central nervous system (brain and spinal cord) where it is present on the myelin sheath 
of oligodendrocytes [231-233]. The disease pathology in the B6 mouse is usually chronic 
progressive and can have phases of partial remission [222, 228]. The disease onset typically 
starts between day 9 and 15 after immunization with tail paralysis, which subsequently ascends 
Table 1.4 Characteristics of conventional T cell subset 
Adapted from [3, 224, 226, 227]
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to the hind- and sometimes also forelimbs [228]. Histologically, MOG-induced EAE in B6 
mice is characterized by perivascular infiltration of mononuclear cells and demyelination in 
the cortex, spinal cord and cerebellum [228, 234]. DCs are thought to pick up the antigen 
and transfer it to the skin-draining lymph node where antigen-specific T cells recognize the 
peptide and are primed in the context of the danger signal provided by the adjuvant. This results 
in the generation of MOG35-55 peptide-specific, encephalitogenic T cells which migrate to the 
CNS where they recognize their cognate antigen presented in the context of MHC-II (H-2b). 
Myeloid cells and T cells mediate the pathogenesis but other cell types may also be critically 
involved [228]. By comparison, B cells, antibodies and complement play an insignificant role 
during demyelination in MOG protein or MOG35-55 peptide-induced EAE in B6 mice due to an 
inability to mount a MOG-specific antibody response capable of recognizing the native protein 
[221]. EAE in the B6 mouse provides an adequate model to study autoantigen- and tissue-
specific T cell responses and, therefore, became one of the most widely used animal models 
for investigating T cell-mediated immunopathologies in autoimmune disease conditions [222].
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2. Results
2.1 FcgR expression in CIDP
2.1.1 Deregulated inhibitory and activating FcγR expression in patients with CIDP  
Humoral immune responses are thought to play a crucial role in mediating peripheral nerve 
damage and represent important pharmacological targets in CIDP [184, 204, 235]. IgG-mediated 
effector functions require the interaction of the antibodies’ Fc fragment with their cognate 
cellular Fc-gamma receptors (FcgR) expressed by innate immune cells and B lymphocytes. 
Most hematopoietic cells express both activating and inhibitory FcgR and the in vivo activity 
of an IgG antibody therefore results from the net effect of engaging both classes of receptors. 
Compared to demographically matched healthy controls, patients with CIDP were previously 
reported to express lower FcgRIIB levels on B cells.  IVIG therapy led to increased levels of 
FcgRIIB and, in some patients, on CD14+ monocytes [157]. Here, we investigated the expression 
profile of activating and inhibitory FcgRs in patients with CIDP before and during IVIG therapy.
Expression of the activating FcγRI and FcγRIIA and the inhibitory FcγRIIB was determined on 
circulating CD19+CD27− naïve and CD19+CD27+ memory B cells and additionally on classical 
CD14highCD16−  and inflammatory CD14lowCD16+ monocytes in untreated patients with CIDP 
(n = 24) compared to demographically matched healthy blood donors (n = 19) (table 4.1). No 
statistically significant differences were detectable in the frequencies of the aforementioned 
immune cell subsets (data not shown). Consistent with earlier reports [157], patients with CIDP 
showed reduced expression levels of FcγRIIB on B cells (figure 2.1A). The reduction in FcγRIIB 
expression was stronger in the CD19+CD27+ memory (p = 0.002) compared to CD19+CD27− 
naïve (p = 0.009) B cell compartment due to a failure of CIDP patients to upregulate or to 
maintain upregulation of FcγRIIB when B cells become memory cells. FcγRIIB expression was 
also reduced in classical CD14+CD16− monocytes (p = 0.046) and tended to be lower in CD16+ 
monocytes (p = 0.216). Expression of the high-affinity activating FcγRI, not expressed on B 
cells, was increased in both monocyte subsets in patients with CIDP (figure 2.1B). Expression 
of the low-affinity FcgRIIA was increased on CD14lowCD16+ monocytes. Thus, expression 
levels of inhibitory versus activating FcγRs are deregulated in untreated patients with CIDP. 
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2.1.2 Effect of IVIG therapy on deregulated FcγR expression 
Studies in various mouse autoimmune disease models provided solid evidence that the anti-
inflammatory activity of IVIG depends on the presence and upregulation of the inhibitory 
FcγRIIB [190, 236, 237]. We analyzed expression levels of FcγRIIB compared to the activating 
FcγRI and FcγRIIA in patients with CIDP before and 2 or 4-8 weeks after IVIG therapy. The 
clinical response rate to IVIG therapy was 87.5 % as defined by improvement of disability 
within 4 weeks after IVIG therapy [184, 238]. Only samples where >100 cells could be detected 
in the final gate were included in the analysis. FcγRIIB expression was induced on both naïve 
Figure 2.1 Deregulated inhibitory and activating FcγR expression in CIDP 
PBMC of CIDP patients and demographically matched healthy controls were stained with 
fluorochrome-coupled antibodies. FcγR expression levels were measured on B cell and 
monocyte subsets by flow cytometry. Median fluorescence intensity (MFI) of FcγRIIB (A) on 
naïve (CD27−) and memory (CD27+) B cells, and classical (CD14highCD16-) and non-classical 
(CD14lowCD16+) monocytes. (B) FcγRI and (C) FcγRIIA MFI on classical (CD14highCD16−) 
and inflammatory (CD14lowCD16+) monocytes. Statistics were performed using the Mann-
Whitney U test. 
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and memory B cells 2 weeks after IVIG therapy (p = 0.007 and 0.004 for naïve and memory B 
cells, respectively) (figure 2.2A). After 4-8 weeks, no further induction of FcγRIIB expression 
on B cells was observed for most patients (Naïve B cells: further induction in 7/20; 35.0 %. 
memory B cells: further induction in 5/17; 29.4 %), but levels remained significant compared to 
baseline values (p = 0.002 and 0.047 for naïve and memory B cells, respectively). On monocyte 
subsets, FcγRIIB expression was upregulated in some patients (CD14highCD16-: 16/23; 69.6 % 
after 2 weeks; 15/22; 68.2 % after 4-8 weeks; CD14lowCD16+: 10/19; 52.6 % after 2 weeks; 
9/20; 45.0 % after 4-8 weeks), but the overall difference was not statistically significant (figure 
2.2A). IVIG therapy was associated with a transient downregulation of the activating FcγRI 
on inflammatory CD14lowCD16+ monocytes after 2 weeks (p < 0.001) (figure 2.2B). After 4-8 
weeks, FcγRI levels did not differ significantly from baseline values (p = 0.18). Monocyte 
expression levels of the low affinity activating FcγRIIA were not significantly regulated by 
IVIG therapy (figure 2.2C). 
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Figure 2.2 IVIG therapy partially restores FcγR expression on B cells and 
monocytes. 
Flow cytometry analysis of FcγR expression on PBMC of treatment-naïve CIDP 
patients before and 2 or 4-8 weeks after a single-dose of IVIG (2 g/kg) treatment. 
Data points for individual patients are connected by lines. For some patients not all 
data points were available. Changes of FcγRIIB (A), FcγRI (B) and FcγRIIA (C) MFI 
following IVIG treatment are shown relative to baseline (untreated). Statistics were 
performed using the Wilcoxon signed rank test. 
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2.2 IgG-Fc glycosylation in patients with CIDP 
Studies in murine models of antibody-mediated autoimmunity suggested that IgG-Fc sialylation 
conveys anti-inflammatory properties to IgG [133, 139]. Therefore, we were interested in the 
regulation of antibody sialylation in human autoimmunity. High-performance chromatography 
with fluorescence detection (HPLC-FL) and lectin blotting were used for the specific detection 
of IgG-Fc glycoforms. 
2.2.1 Frequency of IgG-Fc glycoforms in CIDP patients
According to the number of terminal galactose residues, N-glycans are classified as G0 (no 
galactose residue and, consequently, no sialic acid residue), G1 (one galactose residue), and G2 
(both branches carry a galactose residue) groups. The frequency of these IgG-Fc glycoforms was 
evaluated by high performance anion-exchange chromatography (figure 2.3A) in 19 previously 
untreated patients with CIDP included in the ICE trial [192] (see capter 4.2.1 for further details) 
before randomization to IVIG or placebo treatment and compared to 20 healthy individuals 
matched by age (median age (range): 55 (22-74) for CIDP and 53.5 (21-73) for HD) and gender 
(male to female ratio: 1.7 for CIDP and 1.9 for HD). Total serum IgG levels were similar in 
patients and controls (data not shown). 
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Figure 2.3 Serum IgG-Fc galactosylation. 
(A) Representative HPLC-FL chromatogram of IgG-Fc glycan analysis. The three major IgG-
Fc glycoforms G0 (no galactose), G1 (one galactose), G2 (two galactoses) are indicated with 1, 
2 and 3, respectively. (B) Frequency of agalactosyl (G0) and galactosylated (G1 and G2) IgG-Fc 
glycans in healthy donors (HD) as compared to CIDP patients. GlcNAc, N-Acetylglucosamine; 
Man, mannose; Gal, galactose; Fuc, fucose; Sial, sialic acid. p values by Mann-Whitney U test. 
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The frequency of agalactosyl IgG-Fc was significantly increased in patients with CIDP (figure 
2.3B). Conversely, galactosylated glycoforms were less frequently detected and the ratio of 
galactosyl to agalactosyl IgG-Fc was decreased in CIDP sera. Both G1 and G2 groups were 
reduced in CIDP patients and contributed to the overexpression of agalactosyl N-glycans. Next, 
we analyzed IgG-Fc glycosylation longitudinally in patients with CIDP by Lectin-blotting for 
the detection of individual glycan residues. 
2.2.2 Longitudinal analysis of serum IgG-Fc glycosylation in CIDP patients 
2.2.2.1 Serum IgG concentration
We longitudinally analyzed serum from CIDP patients, who had been were treated with IVIG. 
As we analyzed antibody glycosylation, it was important to assess the influence of IVIG on total 
serum IgG concentration. In the ICE trial cohort, total serum IgG levels in samples obtained 
before and 24 weeks after placebo (n = 18) and IVIG treatment (n = 17) were analyzed. Unlike 
in patients receiving placebo, IVIG treated patients showed a consistent increase in serum IgG-
Fc levels (figure 2.4A). This was not the case in an additional cohort of 33 CIDP patients 
(“Marburg cohort”, see capter 4.2.1 for further details) in whom post-treatment samples were 
taken 3-5 weeks following the last infusion of IVIG (mean ± SD: 4 ± 0.6) and total serum IgG 
levels after IVIG therapy were not significantly increased as compared to pre-treatment samples 
(figure 2.4B).
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Figure 2.4: IVIG treatment leads to an increase of serum IgG content. 
Serum IgG content was measured by ELISA. Relative IgG content compared to study entry is 
shown. (A) Serum of CIDP patients participating in the ICE trial was taken before and 2 weeks 
after the last treatment with IVIG (left) or placebo (right) (B) Patients from an independent 
cohort (“Marburg cohort”) all received IVIG. Serum was taken 3-5 weeks following the last 
infusion of IVIG (mean +/- SD: 4.0 +/- 0.6). (IVIG, intravenous immunoglobulin). Statistics 
were performed by Wilcoxon matched pairs test. 
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2.2.2.2 Induction of IgG-Fc sialylation is associated with disease remission in CIDP 
First, patients from ICE cohort were analyzed. We found that patients with clinical disease 
remission during placebo therapy could be distinguished from those with stable or worsened 
disease by the induction of Fc-sialylation (figure 2.5A). Changes in Fc-galactosylation and 
fucosylation were similar in patients with disease remission compared to stable or worsened 
disease. In contrast, IgG-Fc glycosylation in patients who received IVIG was not associated 
with successful treatment (figure 2.5A). The detected increase of total IgG serum levels 2 
weeks after the last infusion compared to baseline levels (figure 2.4A) precluded profiling of 
endogenous IgG in this cohort. We therefore analyzed serum samples from an independent 
cohort of 33 CIDP patients (“Marburg cohort”, see table 4.3 for further details). In this cohort, 
reduction in clinical disease severity scores upon IVIG therapy was significantly associated 
with an induction of IgG-Fc sialylation. No significant correlation was observed for IgG-Fc 
galactosylation and fucosylation and the reduction of disease severity (figure 2.5B). 
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2.3 Impact of IgG-Fc glycan structure on IgG function
2.3.1 Fc-receptor binding is not affected by IgG-Fc sialylation
In order to investigate the mechanisms by which Fc sialylation may results in remission., 
we purified de-sialylated (neuraminidase treated) and sialic acid enriched Fc (by SNA-lectin 
column-affinity) from IVIG. Successful purification was confirmed by lectin blotting (figure 
2.6A). PBMC were stained with cell-type specific monoclonal antibodies and incubated 
with Fc, sialic acid enriched Fc and neuraminidase treated Fc. Additionally, we obtained an 
homogenously tetra-sialylated glycoform of Rituximab (RTX) prepared by chemoenzymatic 
glycoengineering of commercial RTX (kindly provided by L. X. Wang and J. Giddens) [239] 
(figure 2.6B). Tetra-sialylation refers to the prescence of two sialic acids in present on each of 
the tow IgG-Fc glycans. 
No binding differences of Fc and sialic acid enriched Fc to FcγR expressing monocytes and NK 
cells was found (figure 2.7A). De-sialylated Fc bound slightly better to CD14- monocytes and 
CD56bright NK cells which both express FcγRIIIA. No binding was detecton to B cells, which 
only express the low-affinity FcγRIIB (figure 2.7A).
FcγR binding properties of RTX and tetra-sialylated RTX were analysed using CHO cells 
transfected with one of the human FcγRs (kindly provided by F. Nimmerjahn) [240]. For 
FcγRIIA and FcγRIIIA both of the two most frequent isoforms were analysed. Similar to 
sialic acid enriched Fc, no differences in FcgR binding were detected for tetra-sialylated RTX 
compared to unmodified, non-sialylated RTX (figure 2.7B). 
Figure 2.5 Induction of IgG-Fc sialylation is associated with disease remission in 
CIDP (continued)
(A) Serum IgG-Fc glycan composition of CIDP patients analyzed by lectin blotting. 
Relative IgG-Fc glycan abundance of CIDP patients before and after a 24 weeks observation 
period (1 = no change). Patients undergoing disease remission are compared to those with 
stable or worsening disease (no remission). Statistics were performed by Mann-Whitney 
U test. (B) IgG-Fc glycan composition analysis of CIDP patients before and 3-5 weeks 
after receiving the last IVIG injection. Fold changes in glycan composition are compared 
to disease activity changes reflected by the INCAT overall disability  score (maximal score 
= 10). Statistics were performed by Spearman test.
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Figure 2.6 Confirmation of polyclonal Fc and RTX glycovariants
(A) Lectin immunoblotting of Fc purified from polyclonal IgG and enriched for sialylated Fc 
or de-sialylated (B) Lectin immunoblotting of RTX glycovariants. (mannose: Lens culinaris 
agglutinin; terminal galactose: Erythrina cristagalli lectin; sialic acid: Sambucus nigra 
agglutinin)
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2.3.2 FcγR mediated target cell lysis is not affected by IgG-Fc sialylation
We employed these two glycoforms, i.e. commercial RTX not carrying sialic acid vs. tetra-Fc-
sialylated RTX, to determine whether IgG-Fc sialylation impacts the efficacy of CD20-targeted 
B cell lysis. Incubation of Natural killer (NK) cells with either the unmodified or tetra-Fc-
sialylated antibody resulted in efficient lysis of autologous B cells and the depleting efficacy 
was similar between the two glycoforms (figure 2.8).
Figure 2.7 Sialic acid does not influence FcgR binding properties (continued)
(A) PBMC of a healthy blood donor were stained with cell-lineage specific fluorescent labelled 
antibodies and binding of differentially sialylated polyclonal Fc to lymphocyte subsets was analyzed 
by flow cytometry. (B) Binding of RTX and tetra-sialylated RTX to CHO cells either untransfected 
or transfected with the indicated FcgRs analyzed by flow cytometry.
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2.3.2 IgG-Fc glycan structure regulates complement-dependent cytotoxicity 
2.3.2.1 IgG-Fc tetra-sialylation impairs CDC
Complement-dependent cytotoxicity (CDC) of unmodified RTX and tetra-sialylated RTX was 
analyzed using CD20 expressing Burkitt lymphoma cell lines Raji or Ramos (figure 2.9A and 
C, respectively). In contrast to ADCC, tetra-Fc-sialylated RTX was much less efficient than 
unmodified RTX at inducing CDC of both Raji (figure 2.9B) and Ramos (figure 2.9D) cells.
Figure 2.8 ADCC is not affected by Fc sialylation
(A) RTX and tetra-sialylated RTX mediated lysis of B cells (targets) by autologous NK cells 
(effectors). (B) Representative experiment and quantification of 3 independent experiments. 
Statistics were performed by t-test.
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Figure 2.9 IgG-Fc tetra-sialylation impairs CDC 
(A) CD20 expression of Raji cells analyzed by flow cytometry. Grey histograms, unstained cells; 
open histograms, stained cells. (B) Complement-mediated lysis of Raji cells. Representative 
experiment and quantification of EC50 of 4 independent experiments. Statistics were performed 
by t-test. (C) CD20 expression of Ramos cells analyzed by flow cytometry. Grey histograms, 
unstained cells; open histograms, stained cells. (D) Complement-mediated lysis of Raji cells. 
Representative experiment and quantification of EC50 of 3 independent experiments. Statistics 
were performed by t-test.
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2.3.2.2 Generation and characterization of RTX and hu8-18C5 glycovariants
To confirm that CDC differences are independent of antibody processing and not restricted to 
RTX we used β1,4 galactosyltransferase-1 (b1,4GalT) and α2,6-sialyltransferase (ST6Gal1) 
enzymes in the presence of the corresponding sugar nucleotide substrates for the enrichment 
of mono- and bi-sialylated antibody species[87, 165, 241]. An SNA lectin-affinity column 
was used to further enrich enzymatically galactosylated and sialylated antibodies for species 
containing at least two sialic acids per antibody [242]. RTX and a humanized version of the 
MOG-reactive 8-18C5 (hu8-18C5) antibody [243] were used. The chosen antibodies did not 
contain N-glycosylation sites in their F(ab`)2 domain (figure 2.10) allowing us to ensure that 
any glycan modification is restricted to the IgG-Fc N-glycans. 
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We generated galactosylated, galactosylated and sialylated as well as de-galactosylated variants 
of the antibodies. Lectin-blotting was performed to confirm the glycan profile and to determine 
the approximate relative contribution of the individual glycan species in the final product (figure 
2.11).
Figure 2.10 RTX and hu8-18C5 N-glycosylation sites. 
(A) Amino acid sequence of RTX and hu8-18C5 heavy chain (HC) and light chain (LC) were analyzed 
for potential N-glycosylation sites. Both antibodies only contain the conserved Fc-N-glycosylation 
site at asparagine 297 (N297, depicted in bold) and no glycosylation sites in the HC and LC variable 
regions. N-glycosylation sites (Asn-Xaa-Ser/Thr) were identified using the NetNGlyc 1.0 server 
from the Technical University of Denmark (DTU). RTX sequences were obtained from www.
drugbank.ca (Acc. Nr. DB00073) and hu8-18C5 sequences were translated from the expression 
plasmids. (B) SDS-Polyacrylamide gel electrophoresis of RTX and hu8-18C5. Silver staining (left 
lane) and immunoblotting (right lane) using the mannose-specific lectin Lens culinaris agglutinin. 
(HC, heavy chain; LC, light chain)
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To confirm the integrity and functionality of the generated antibodies, binding of RTX and 
hu8-18C5 antibody glycovariants to their cognate antigen was tested. To do so, a human 
oligodendroglial cell line (MO3.13) transduced to express human full-length MOG cDNA 
[244] (MO3.13 MOG, figure 2.12A) was used as a target for hu8-18C5 and CD20+ Raji cells for 
RTX. As shown in figure 2.12B and C, galactosylation and sialylation led to a slightly increased 
antigen-binding capacity. Contrary, tetra-sialylation of RTX led to decreased antigen binding 
(figure 2.12B).  
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Figure 2.11 Confirmation of antibody glycovariants by lectin immunoblotting
(A) Lectin immunoblotting of RTX glycovariants. (B) Lectin immunoblotting of hu8-18C5 
glycovariants. (C) Relative abundance of individual IgG-Fc glycans in the antibody glycovariants. 
Terminal galactose refers to an IgG-Fc linked galactose not succeeded by sialic acid. 
Figure 2.12 MO3.13 MOG cell line antigen expression antigen binding properties of antibody 
glycovariants (continued on next page)
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2.3.2.3 IgG-Fc sialylation as well as de-galactosylation impairs CDC
CDC was assessed for unmodified RTX using Raji cells as targets and for hu8-18C5 using 
MO3.13 MOG cells. Enzymatic enrichment of RTX or hu8-18C5 for sialylated glycoforms 
recapitulated the reduced CDC of tetra-sialylated RTX (figure 2.13A and B). As both sialic-
acid enriched RTX variants (tetra-sialylated and galactosylated & sialylated) also have a higher 
galactose contant than unmodified RTX, we next analyzed the relative influence of galactose 
and sialic acid on CDC. As shown in figure 2.13C, galactose-enrichment of RTX did not alter 
CDC compared to the unmodified antibody whereas the addition of sialic acid to the previously 
galactosylated antibody resulted in reduced CDC and also de-galactosylation of the unmodified 
RTX compromised CDC to a similar extent. Based on these findings, we set out to further 
elucidate the underlying mechanism of IgG-Fc glycan mediated CDC regulation by dissecting 
its influence on the individual steps of the classical complement cascade. 
2.3.3 Fc-sialylation inhibits increased C1q binding of Fc-galactosylated IgG
The classical complement pathway is triggered by binding of C1q to the Fc domain in 
antibody:antigen complexes leading to autoactivation of the C1 complex (comprising C1q, 
C1r and C1s) and activation of complement by cleavage of C4 and C2. The resulting C4bC2a 
convertase cleaves C3 causing the covalent coupling of C3b to reactive surfaces such as the cell 
membrane which culminates in the formation of the membrane attack complex and lysis of the 
target cell [245]. The binding affinity of C1q for murine IgG was shown to be reduced upon 
the removal of galactose from the IgG-Fc linked glycan [116]. To investigate the mechanism 
by which Fc-sialylation impacts complement-mediated cytotoxicity, we tested galactosylated, 
sialylated, and de-galactosylated Fc glycovariants of RTX and hu8-18C5 for their ability to 
bind C1q and induce complement activation.
Figure 2.12 MO3.13 MOG cell line antigen expression antigen binding properties of antibody 
glycovariants (continued)
(A) MO3.13 cells lentivirally transduced to express human myelin oligodendrocyte glycoprotein 
(MOG) and FACS-sorted for MOG positive cells were analyzed for MOG expression by flow 
cytometry. Grey histograms, unstained cells; open histograms, stained cells. CD20+ Raji cells 
were incubated with RTX or glycovariants of RTX (B) or MO3.13 MOG cells with hu8-18C5 
(anti-MOG) or glycovariants of hu8-18C5 (C) following incubation with a fluorescently labeled 
anti-Ig antibody and detection of antibody binding by flow cytometry. (MFI, median fluorescence 
intensity) 
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Figure 2.13 IgG-Fc galactose and sialic acid content influence CDC 
(A) CDC of Raji cells with RTX or galactosylated and sialylated RTX (B) CDC of MO3.13 
MOG with hu8-18C5 or galactosylated and sialylated hu8-18C5. (C) CDC of Raji cells with 
RTX glycovariants. Representative experiment (left) and quantification of EC50 of 3 independent 
experiments (right). EC50 obtained for unmodified RTX was set to 1 and the relative EC50 was 
calculated. Statistics were performed by t-test.
41
Results
2.3.3.1 C1q binding to antibody glycovariants
The generated antibody glycovariants of RTX and hu8-18C5 (figure 2.6B and 2.11) were used 
in combination with the respective target cell lines (Raji and Ramos) for RTX and MO3.13 
MOG for hu8-18C5) to analyze cell-surface deposition of C1q. To avoid cell lysis by CDC, C5 
depleted serum was used. Incubation of the antibodies with their target cells in the presence of 
human serum complement led to rapid binding of C1q (figure 2.14A and B). Fc-galactosylation 
of unmodified antibodies resulted in a markedly increased capacity to bind C1q. Subsequent 
addition of sialic acid abrogated increased C1q binding of Fc-galactosylated IgG. Fully tetra-
Fc-sialylated RTX was largely devoid of C1q binding (figure 2.14A-E). To investigate whether 
these effects can be transferred to polyclonal IgG, Fc purified from IVIG and enriched for 
sialylated Fc or de-sialylated, i.e. terminally galactosylated (figure 2.6A) was analyzed for 
C1q binding in ELISA. Similar to the monoclonal IgGs tested, the presence of more terminal 
galactosylated (as a result of de-sialylation) resulted in increased C1q binding. Conversely, the 
enrichment for sialic acid-containing IgG-Fc led to reduced C1q binding (figure 2.14F). 
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2.3.3.2 IgG-Fc glycosylation influences C3b deposition
Next, we investigated whether the capacity of Fc-sialylation to block C1q binding also translates 
into decreased downstream activation of complement proteins. As shown in figure 2.15, levels 
of C3b deposition to the cell surface were also decreased upon antibody sialylation or de-
galactosylation. However, the markedly increased levels of C1q binding to galactosylated 
antibodies did only partially translate into increased C3b deposition. 
Figure 2.14 C1q binding to IgG Fc glycovariants. (continued)
(A) Time-course of C1q binding to CD20+ Raji cells in the presence or absence 
of differentially glycosylated RTX. Mean and SEM of at least three independent 
experiments. Median fluorescence intensity obtained for the unmodified antibody 
after 60 minutes was set to 100 and the relative signals were calculated. (B) 
Time-course of C1q binding to MO3.13 MOG cells in the presence or absence of 
differentially glycosylated variants of hu8-18C5 (anti-MOG). Mean and SEM of at 
least 3 independent experiments. (C) Quantification of RTX antibody-glycovariant 
dependent C1q binding to CD20+ Raji (left) and Ramos (right) cells after 30 
minutes incubation. Mean and SEM of at least 3 independent experiments. Statistics 
were performed by t-test. (D) Quantification of hu8-18C5 antibody-glycovariant 
dependent C1q binding to MO3.13 MOG cells after 30 minutes. Statistics were 
performed by t-test. (E) Representative flow cytometry stainings showing C1q 
binding to the indicated cell type and antibody after one hour incubation. (F) C1q 
binding to differentially glycosylated Fc measured by ELISA. Mean and SEM of 
three independent experiments. C1q binding was normalized to unmodified Fc at 
10 % serum. Individual curves were compared to Fc using 2-way ANOVA and 
Bonferroni posttest comparing Fc and de-sialylated Fc (p values above curve) or 
Fc and sialic acid enriched Fc (p values below curve)
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These data indicate that Fc-sialylation exerts immunoregulatory functions through inhibition 
of C1q binding and subsequent initiation of the classical complement pathway, leading to 
reduced CDC. 
Figure 2.15 IgG-Fc sialylation reduces C3b deposition. 
C3b deposition to Raji cells in the presence or absence of 10 µg/ml RTX or glycovariants of RTX 
analyzed by flow cytometry (A) and quantification of C3b deposition after 30 minutes (B) Mean and 
SEM of 3 independent experiments. For inter-assay normalization the median fluorescence intensity 
signal obtained for the unmodified antibody after 60 min was set to 100 and the relative signal was 
calculated for all other data points; p values by t test. 
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2.4 IVIG treatment of T cell mediated autoimmunity
Pooled polyclonal human IgG (referred to as IVIG, intravenous immunoglobulin) was shown 
to be an efficient treatment of several antibody-mediated autoimmune disease models [139, 
152, 236] and its protective effect was mainly attributed to the Fc domain of IgG [133, 158, 
161, 165]. Similarly, IVIG was shown to ameliorate T cell mediated autoimmunity [246] but its 
mechanism of action is incompletely understood [166, 247]. We therefore aimed to investigate 
the requirement of F(ab`)2 and Fc as well as its mode of action for the protective effect in EAE. 
2.4.1 Therapeutic efficacy of IVIG in EAE
First we established which timing and dosage of IVIG is required in order to ameliorate EAE. 
IVIG was given daily starting one day before CFA + MOG35-55 immunization. As shown in 
figure 2.16A, low-dose IVIG (0.01 g/kg) slightly worsened the disease whereas high dose IVIG 
(1 g/kg) completely protected animals from disease development. Treatment from one day 
before CFA + MOG35-55 immunization until day 6 led to delayed onset of disease and reduced 
severity whereas treatment from day 7 increased EAE severity (figure 2.16B). Therefore, IVIG 
is required at high dose and continuously for its protective effect.
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Figure 2.16 Timing and dosage of IVIG treatment
EAE was induced in C57BL/6 mice by immunization with MOG35-55 peptide in CFA and mice 
were treated i.p. with IVIG or PBS starting one day before EAE induction and every day 
thereafter (or as indicated). (A) Titration of IVIG treatment. (B) Timing of IVIG treatment. 
Means and SEM are shown. n = 4 animals per group 
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2.4.2 FcgRIIB may be dispensable for the protective effect of IVIG
Treatment of autoimmunity with IVIG has been shown to be dependent on FcgRIIB in several 
animal models [139, 158]. We immunized C57BL/6 mice deficient of FcgRIIB-/- and compared 
the disease development to their heterozygous littermates (FcgRIIB+/-). No difference in the 
disease course was found (figure 2.17A). Treatment of FcgRIIB-/- animals with IVIG led to a 
delayed disease onset and reduced severity (figure 2.17B). FcgRIIB may therefore be dispensable 
for the protective effect of IVIG in EAE. 
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2.4.3 F(ab’)2 is sufficient for the protective effect of IVIG
We next addressed which functional domain of IVIG (IgG) is required for protection of EAE. 
Therefore, the Fc portion of IVIG-derived IgG was removed by cleavage with Ide-S [248] and 
F(ab’)2 was purified by size-exclusion (see figure 4.7).
CFA + MOG35-55 immunized mice were treated with equimolar amounts of IVIG (0.5 g/kg), 
F(ab’)2 (0.33 g/kg) or PBS starting one day before immunization. F(ab’)2 fragments completely 
recapitulated the protective effect of IVIG for both disease severity (figure 2.18A) and disease 
incidence (2.18B).   
Figure 2.17 EAE disease course and IVIG treatment response in FcgRIIB-/- mice
(A) EAE was induced in C57BL/6 mice deficient for FcgRIIB (FcgRIIB-/-) and their heterozygous 
littermates (FcgRIIB+/-) by immunization with MOG35-55 peptide in CFA. Means and SEM are 
shown. n = 5 to 6 animals per group. (B) IVIG treatment of FcgRIIB-/- starting one day before EAE 
induction and every day thereafter. Means and SEM are shown. n = 4 animals per group. 
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2.4.4 IVIG does not ameliorate adoptively transferred EAE
The observation that withdrawal of IVIG at day 6 led to delayed disease onset (figure 2.16B) 
and previous reports clearly demonstrating an essential role for T cells during the development 
EAE [219, 249-251] raised the question how T cell responses are shaped by IVIG. To separate 
T cell priming from the encephalitogenic effector phase, we used adoptive transfer EAE. Spleen 
and lymph node (LN) cells from CFA + MOG35-55 immunized mice carrying the transgenic 2D2 
T cell receptor recognizing MOG35-55 peptide [252] (2D2 mice) were in vitro re-stimulated with 
IL-23 and MOG35-55 peptide and adoptively transferred into naïve B6 wildtype (wt) mice. IVIG 
treatment (1 g/kg) was started one day before the cell transfer and continued daily throughout the 
experiment. Both experimental groups developed comparable EAE symptoms (figure 2.19A), 
suggesting the IVIG treatment cannot inhibit disease development once the encephalitogenic 
immune response got initiated. 
To test if MOG-reactive T cells develop at all in IVIG treated CFA + MOG35-55 immunized mice, 
we purified spleen and LN cells from CFA + MOG35-55 immunized mice either untreated (PBS) 
or treated with IVIG. After in vitro re-stimulation with IL-23 and MOG35-55 peptide, cells were 
transferred into naïve mice and EAE disease progression was monitored. No difference was 
found between the groups (figure 2.19B) suggesting that IVIG treatment does not prevent the 
development and/or expansion of MOG specific T cells but rather inhibits their encephalitogenic 
capacity, an observation that has also been previously made in Lewis rats [253]. 
Figure 2.18 F(ab’)2 is sufficient for the protective effect of IVIG
EAE was induced in C57BL/6 mice by immunization with MOG35-55 peptide in CFA and mice were 
treated i.p. with Buffer (PBS + 50 mM arginine + 50 mM glutamic acid), IVIG or F(ab’)2 starting 
one day before EAE induction and every day thereafter. Disease severity (A) and incidence (B) are 
shown. n = 12 animals per group. Individual curves in (A) were compared to Buffer using 2-way 
ANOVA and Bonferroni posttest. 
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2.4.5 Modulation of leukocytes by EAE induction and F(ab’)2 treatment
To get an insight into how F(ab’)2 can prevent the development of EAE, we purified spleen and 
draining lymph nodes (dLNs) 9 days after immunization with CFA + MOG35-55 or CFA + PBS. 
Comparison of the two groups was used to see if the overall activation of the immune system by 
the adjuvant (CFA) is altered or only a specific response towards the encephalitogenic peptide 
(MOG35-55). Mice received daily i.p. injections with PBS or 0.33 mg/kg F(ab’)2 starting one 
day before immunization and every day thereafter. Compared to naïve mice, CFA + PBS or 
CFA + MOG35-55 immunization resulted in increased splenic cellularity in both PBS and F(ab’)2 
treated animals (figure 2.20B). The cellularity of dLNs was less altered and no difference was 
found between F(ab’)2 or PBS treated animals. We next analyzed the frequency and absolute 
numbers of CD4 and CD8 T cells by flow cytometry (figure 2.20A and C). F(ab’)2 treatment 
led to a reduction in frequency and absolute CD4 and CD8 T cell numbers in the spleen of CFA 
+ MOG35-55  immunized animals whereas dLNs showed the opposite trend. Changes in CFA + 
PBS immunized animals largely phenocopied CFA + MOG35-55 immunized animals. 
Figure 2.19 IVIG treatment does not ameliorate adoptively transferred EAE
(A) EAE was induced by adoptive transfer of 1 × 107 cells derived from CFA + MOG35-55 immunized 
2D2 mice 6 days post immunization and in vitro re-stimulation with IL-23 and MOG35-55 peptide 
for 2 days into naïve C57BL/6 mice. Mice received daily i.p. injection of IVIG (1 g/kg) or PBS 
starting one day before immunization. Means and SEM are shown. n = 10 animals per group (B) 
C57BL/6 mice were CFA + MOG35-55 immunized  immunized and treated with PBS or IVIG (1 
g/kg i.p.) treatment starting one day before immunization and daily thereafter. Spleen and LN 
cells were harvested 6 days post immunization and re-stimulated with IL-23 and MOG35-55 for 
2 days. From these cultures 1 × 107 cells were injected i.p. in naïve C57BL/6 mice and disease 
progression was monitored. Means and SEM are shown. n = 4 animals per group. 
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Figure 2.20 Leukocyte and T cell frequencies and total cell numbers following CFA + PBS or 
CFA + MOG35-55 immunization and F(ab’)2 treatment. 
Mice were immunized subcutaneously with CFA and PBS (squares) or CFA and MOG35-55 peptide 
(circles) and injected subcutaneously with PBS (open symbols) or F(ab’)2 (closed symbols). Naïve mice 
(open diamonds) remained untouched. Spleens and dLNs were isolated on day 9 after immunization. 
(A) Representative sequential flow cytometry gating strategy to identify living, singular leukocytes 
as used for all subsequent analysis of leukocyte subsets. Anti-CD4 and anti-CD8 staining was used 
to identify conventional T cell subsets (B). Total number of purified leukocytes in spleens and dLNs 
measured by CASY cell counter. (C) Frequency and total numbers of CD4+ and CD8+ T cells in spleen 
and dLNs. (continued on next page)
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2.4.5.1 Modulation of CD4 T cells by EAE induction and F(ab’)2 treatment
MHC-II restricted CD4 T cells are sufficient to adoptively transfer EAE disease to naïve 
mice indicating a predominant role of this T cell subset for disease development [219, 254]. 
We therefore analyzed the overall distribution of CD4+ T cell subsets (figure 2.21) and their 
cytokine secretion profile (figure 2.22). Regulatory T cells (Tregs) were identified by the 
expression of the transcription factor FoxP3. F(ab’)2 treatment led to increased frequency of 
Tregs in spleen and reduced frequency in dLNs. However, absolute numbers remained largely 
unchanged in all experimental groups. Compared to naïve mice, the CD4+ T cell composition 
of immunized animals showed increased frequencies of central and effector memory T cells 
and reduced frequencies of naïve T cells. In particular, effector memory T cells were increased 
in absolute numbers in both spleen and dLNs. F(ab’)2 treatment reduced the expansion of 
naïve, central memory and effector memory CD4+ T cells in the spleen of CFA + MOG35-55 
immunized animals. CFA + PBS immunized mice showed less expansion and no significant 
reduction upon F(ab’)2 treatment. To further analyze the functional profile of CD4+ T cells, 
purified cells from spleen and dLNs were in vitro re-stimulated with PMA and ionomycin to 
induce cytokine production following intracellular cytokine staining for IFN-g, GM-CSF and 
IL-17 (figure 2.22 A). CFA + PBS and CFA + MOG35-55 immunized animals resembled each 
other in most parameters analyzed with the exception that CFA + MOG35-55 immunized animals 
showed reduced frequency and absolute numbers of cytokine-producing CD4+ T cells in the 
dLNs. F(ab’)2 treatment reduced the frequency of cells producing IFN-g, GM-CSF or IL-17 in 
spleen and dLNs and the absolute numbers of CFA + MOG35-55 immunized animals in the spleen 
and CFA + PBS animals in the dLNs.   
Results of two independent experiments with 7 to 8 animals per group are shown. Statistics by Mann 
Whitney U test. p value above non-capped lines represents comparison of the subjacent groups to 
naïve mice. p values for the comparison of CFA + PBS and CFA + MOG35-55 immunized animals are 
not shown. Only p values reaching significance (< 0.05) are shown. dLNs, draining lymph nodes; 
CFA, complete Freund’s adjuvant; MOG, myeloid oligodendrocyte glycoprotein; PBS, phosphate 
buffered saline; SSC-a, side scatter-area; FSC-A, FCS-area; FSC-H, FSC-height.
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Figure 2.21: Distribution of CD4 T cell subsets following CFA + PBS or CFA + MOG35-55  
immunization and F(ab’)2 treatment. 
Mice were immunized subcutaneously with CFA and PBS (squares) or CFA and MOG35-55 peptide 
(circles) and injected subcutaneously with PBS (open symbols) or F(ab’)2 (closed symbols). Naïve mice 
(open diamonds) remained untouched. Spleens and dLNs were isolated on day 9 after immunization. 
(A) Exemplary sequential flow cytometry gating strategy. Living, singular leukocytes were gated as 
described in figure 2.20. Intracellular staining for the transcription factor FoxP3 was used to identify 
Tregs. Non-Tregs were analyzed for CD62L and CD44 to distinguish naïve, central and effector 
memory T cells. (B) Frequency of the individual subset among CD4+ T cells (left two columns) and 
their total numbers (right two columns) in spleen and dLNs. Results of two independent experiments 
with 7 to 8 animals per group are shown. Statistics by Mann Whitney U test. p value above non-capped 
lines represents comparison of the subjacent groups to naïve mice. p values for the comparison of CFA 
+ PBS and CFA + MOG35-55 immunized animals are not shown. Only p values reaching significance 
(< 0.05) are shown. dLNs, draining lymph nodes; CFA, complete Freund’s adjuvant; MOG, myeloid 
oligodendrocyte glycoprotein; PBS, phosphate buffered saline; Treg, regulatory T cells.
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Figure 2.22: Cytokine profile of CD4 T cells in mice after CFA + PBS or CFA + MOG35-55 
immunization and F(ab’)2 treatment. 
Mice were immunized subcutaneously with CFA and PBS (squares) or CFA and MOG35-55 peptide 
(circles) and injected subcutaneously with PBS (open symbols) or F(ab’)2 (closed symbols). Naïve mice 
(open diamonds) remained untouched. Spleens and dLNs were isolated on day 9 after immunization. 
Cells were re-stimulated for 4 hours with PMA and ionomycin in the presence of Brefeldin A to block 
cytokine secretion.  Intracellular staining with fluorescently labeled monoclonal antibodies was used 
to detect cytokine production. (A) CD4 T cells were identified by flow cytometry as described in 
figure 2.20. Exemplary cytokine stainings are shown in comparison to CD44 cell-surface expression, 
which identifies activated T cells. (B) Frequency of cytokine producing cells among CD4+ T cells (left 
two columns) and total numbers (right two columns) in spleen and dLNs. (continued on next page) 
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2.4.5.2 Modulation of B cells and myeloid cells by EAE induction and F(ab’)2 treatment
Reduced expansion of CD4 T cells as well as their functional capacity upon F(ab’)2 treatment 
could be due to a direct effect on T cells or by modulation of the underlying responses of innate 
immune cells. We therefore analyzed the frequencies, absolute numbers and activation state 
of innate immune cells and B cells by flow cytometry (figure 2.23 – 2.25). Leukocyte subsets 
were identified as indicated in figure 2.20. B cells were identified by co-expression of CD19 and 
MHC-II. Dendritic cells (DCs) co-express high levels of MHC-II and CD11c and were further 
subdivided in CD8+ and CD8- DCs. Neutrophils are co-expressing Ly6G and Ly6C. Monocytes 
stain highly positive for Ly6C and co-express CD11b. 
Results of two independent experiments with 7 to 8 animals per group are shown. Statistics by Mann 
Whitney U test. p value above non-capped lines represents comparison of the subjacent groups to 
naïve mice. p values for the comparison of CFA + PBS and CFA + MOG35-55 immunized animals are 
not shown. Only p values reaching significance (< 0.05) are shown. dLNs, draining lymph nodes; 
CFA, complete Freund’s adjuvant; MOG, myeloid oligodendrocyte glycoprotein; PBS, phosphate 
buffered saline.
Figure 2.23: Identification of B cells and myeloid cell subsets by flow cytometry
Sequential flow cytometry gating to identify B cells and myeloid cell subsets in spleen and 
lymph nodes. Living, single leukocytes were identified as shown in figure 2.20. B cells were 
identified by co-expressing CD19 and MHC-II. DCs were identified by their high expression 
of both CD11c and MHC-II. CD8 was used to discriminate the two functional subsets of DCs. 
Neutrophils were identified as being positive for Ly6G and Ly6C. Finally, monocytes were 
identified by electronic gating on non-B cells and non-neutrophils and their co-expression 
Ly6C and CD11b.
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Figure 2.24: Frequency and absolute numbers of myeloid cells and B cells in mice following 
CFA + PBS or CFA + MOG35-55 immunization and F(ab’)2 treatment. 
Mice were immunized and treated as described in Figure 2.22. Subsets were identified by flow 
cytometry as described in figure 2.23. Frequency (left two columns) and total numbers (right two 
columns) of B cells, neutrophils, monocytes as well as CD8− and CD8+ DCs are shown.
Results of two independent experiments with 7 to 8 animals per group are shown. Statistics by Mann 
Whitney U test. p values above non-capped lines represents comparison of the subjacent groups to 
naïve mice. p values for the comparison of CFA + PBS and CFA + MOG35-55 immunized animals are 
not shown. Only p values reaching significance (< 0.05) are shown. dLNs, draining lymph nodes; 
CFA, complete Freund’s adjuvant; MOG, myeloid oligodendrocyte glycoprotein; PBS, phosphate 
buffered saline; DCs, dendritic cells.
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Figure 2.25: Expression levels of MHC-II and CD80 on myeloid cells and B cells in mice 
following CFA + PBS or CFA + MOG35-55  immunization and F(ab’)2 treatment. 
Mice were immunized and treated as described in Figure 2.22. Subsets were identified by 
flow cytometry as described in figure 2.23. MFI of MHC-II and CD80 on B cells, neutrophils, 
monocytes as well as CD8 positive and negative DCs are shown. (continued on next page)
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Similar to what was found for T cells, the frequency, absolute numbers and activation state 
of B cells and myeloid cells in CFA + PBS and CFA + MOG35-55 immunized animals largely 
resembled each other in most parameters analyzed (figure 2.24 and 2.25). In the spleen, a 
pronounced increase in neutrophils and monocytes results in reduced frequencies of B cells and 
CD8− DCs. However if total numbers are analyzed, all subsets increase upon immunization. 
dLNs of immunized animals contained increased frequencies and total numbers of monocytes, 
neutrophils and CD8- DCs. B cells numbers also tend to be elevated. The most prominent effect 
of F(ab’)2 is a reduction of neutrophils in spleen and dLNs and an increase of monocytes in the 
spleen. 
Next, cell surface expression of MHC-II and the co-stimulatory molecule CD80 (also known 
as B7-1) were analyzed (figure 2.25). Again, both molecules were regulated similarly in CFA 
+ PBS and CFA + MOG35-55 immunized animals. Immunization led to increased expression of 
MHC-II on B cells, neutrophils and monocytes in the spleen and on B cells and neutrophils in 
dLNs. In contrast, the MHC-II expression level on DC in the spleen remained largely unchanged 
and was markedly reduced on CD8− DC in dLNs. F(ab’)2 treatment reduced MHC-II expression 
on neutrophils, monocytes and both subsets of dendritic cells in the spleen of CFA + MOG35-55 
immunized animals. On DCs, MHC-II was reduced below the levels found on naïve mice. In 
contrast, MHC-II expression in dLNs was hardly effected by F(ab’)2 treatment. Immunization 
resulted in increased expression of CD80 on B cells, neutrophils (CFA + PBS group only) and 
monocytes in the spleen and on B cells and neutrophils in dLNs. Immunization hardly affected 
the expression of CD80 on CD8− DCs (with the exception of increased expression in dLNs of 
CFA + PBS immunized mice) and CD8+ DCs from dLNs. In contrast, spleen-derived CD8+ 
DCs reduced the expression of CD80 upon immunization. F(ab’)2 treatment reduced CD80 
expression on B cells (CFA + MOG35-55 group only), neutrophils, monocytes and CD8− DCs 
of the spleen. CD80 expression on neutrophils and CD8− DCs was even below the level of 
naïve mice. In dLNs, F(ab’)2 treatment led to reduced CD80 expression on B cells, neutrophils, 
monocytes (CFA + MOG35-55 group only) and CD8− DCs (CFA + PBS group only).  
Collectively, these data indicate that F(ab’)2 treatment prevents the development of 
encephalitogenic T cells by reducing the overall inflammatory state. This is indicated by 
reduced neutrophilia and reduced expression of MHC-II and CD80 on professional and non-
professional antigen presenting cells. 
Results of two independent experiments with 7 to 8 animals per group are shown. Mice were 
excluded if less than 10 signals (cells) were present in the final gate (this was the case for some 
neutrophil-, monocyte- and DC gates in dLNs of few mice). Statistics by Mann Whitney U test. 
p values above non-capped lines represents comparison of the subjacent groups to naïve mice. p 
values for the comparison of CFA + PBS and CFA + MOG35-55 immunized animals are not shown. 
Only p values reaching significance (< 0.05) are shown. dLNs, draining lymph nodes; CFA, 
complete Freund’s adjuvant; MOG, myeloid oligodendrocyte glycoprotein; PBS, phosphate 
buffered saline; DC, dendritic cell; MFI, median fluorescence intensity.
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3. Discussion
This study aimed to investigate the mechanisms responsible for the regulation of IgG-mediated 
anti-inflammatory properties in humans and mice. We found that clinical disease remission 
in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune 
disease of the peripheral nervous system during which humoral immune responses are central in 
mediating tissue damage, is associated with deregulated expression of activating and inhibitory 
FcgRs and with changes in the IgG-Fc glycan profile. IVIG treatment partially restored FcgR 
expression and disease remission correlated with increased IgG-Fc sialylation. We demonstrate 
that Fc sialylation impairs IgG’s capability to activate the complement system resulting in 
reduced complement-mediated cytotoxicity. Finally, studies in EAE revealed that IVIG can also 
induce F(ab’)2-mediated anti-inflammatory pathways indicating that more than one mechanism 
may be responsible for its therapeutic efficacy during autoimmunity. 
Balanced signaling through activating and inhibitory FcγRs regulates innate and adaptive 
immune responses [94, 255] and impairment of the FcγR regulatory system is associated 
with an increased susceptibility to develop autoimmune pathologies [97, 256-259]. Whereas 
deficiency in activating Fc receptors renders mice resistant to autoimmunity in several disease 
models [256, 260, 261], mice lacking FcgRIIB show an autoimmune-prone phenotype [97, 258, 
259]. The latter appears to be partly dependent on the genetic background of the mice [257]. 
In addition, analysis of genetic polymorphisms partially confirms the relevance of FcgRs in 
human autoimmunity: polymorphisms leading to higher-affinity variants of activating FcgRIIA 
(FcgRIIA 131H) [262, 263] have been associated with systemic lupus erythematosus (SLE) and 
the high-affinity variant of FcgRIIIA (FcgRIIIA 158V) with SLE [264] and rheumatoid arthritis 
(RA) [265]. The available data for FcgRIIB are still contradictory. A loss of function mutation 
of FcgRIIB (FcgRIIB 232T) [266] has been associated with SLE in some patient cohorts [267, 
268] but not in others [269, 270]. In addition, a promotor region associated with increased 
expression of FcgRIIB was also found to be associated with SLE [271]. 
We found that patients with CIDP have increased expression levels of activating FcgRI and 
FcgRIIA on blood monocytes but decreased expression of FcgRIIB on blood monocytes and naïve 
and memory B cells. Reduced FcgRIIB expression in CIDP has been previously reported [157] 
and could be potentially explained by functionally relevant single-nucleotide polymorphisms 
(SNPs) in the FcγRIIB promoter [271, 272] which are associated with autoimmune phenotypes 
and have been found to be associated with CIDP [157]. A recent study in humanized mice 
showed that alleles encoding functionally impaired FcgRIIB variants lead to higher frequencies 
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of plasmacytoid B cells, increased serum antibody levels and generation of autoantibodies, 
confirming the importance of FcgRIIB for humoral immune tolerance in the human immune 
system [273]. FcgRIIB regulates B cell activation and homeostasis [100, 274] and the balance 
between FcgRIIA and FcgRIIB was shown to set the threshold for the activation of monocyte-
derived DCs [94]. Increased monocyte expression of the activating FcγRI was identified as 
a potential biomarker for disease activity in patients with SLE and RA in whom monocyte 
expression levels of FcγRI are significantly higher in active compared to inactive disease [275]. 
Our data indicate that deregulated monocyte expression of FcgRI is not confined to patients 
with SLE and RA. FcgRI expression is induced by interferon-α (IFN-α), among other cytokines, 
and increased FcgRI levels on monocytes derived from SLE patients were attributed to higher 
IFN-α production in these patients [275]. A role for IFN-α in the pathogenesis of CIDP is less 
well established, although some studies report increased levels of type I IFN signaling in CIDP 
patients [276] or development of CIDP associated with IFN-α therapy [277-283]. Activation 
of FcgRI on monocytes triggers differentiation into immature dendritic cells that induce 
autoreactive T cell responses and has therefore been implicated to mediate tissue injury in 
antibody-mediated autoimmune diseases [284]. FcgRI-mediated activation and differentiation 
of myeloid cells might also contribute to peripheral nerve damage in CIDP, where myeloid cells 
are believed to be the main local effector cells [235].
The analysis of concomitant expression of activating and inhibitory FcgRs indicates that the 
FcgR regulatory system rather than expression levels of a single receptor is disturbed in patients 
with CIDP. Altogether, these data suggest that deregulated expression of activating versus 
inhibitory FcgRs might lower the activation threshold for myeloid cells and B cells [94, 285], 
thereby contributing to the susceptibility to develop CIDP [286]. 
Since the discovery of the anti-inflammatory properties of pooled high-dose gammaglobulins 
in Idiopathic thrombocytopenic purpura (ITP) [140, 141], IVIG has been approved for several 
autoimmune diseases including ITP, Kawasaki’s disease, CIDP and multifocal motor neuropathy 
(MMN) [142]. Clinical efficacy in ITP [155] and studies in animal models [133, 158, 159, 165] 
suggest that IgG-Fc mediates the anti-inflammatory actions of IVIG. Several [139, 158] but 
not all [287-289] animal models of autoimmunity also found that signaling via the inhibitory 
FcgRIIB is required for IVIG to protect from the development of autoimmunity. Additionally, 
in murine models of ITP, RA and nephrotoxic nephritis IVIG administration results in an up-
regulation of FcγRIIB surface expression on effector macrophages or enhanced recruitment of 
FcγRIIB positive myeloid cells to the site of inflammation [158, 236]. Our data suggest that 
restoration of deregulated activating versus inhibitory FcγR expression might contribute to the 
clinical efficacy of IVIG in CIDP patients. IVIG treatment in CIDP patients requires repeated 
infusions in order to maintain a clinical benefit [192]. Notably, upregulation of the inhibitory 
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FcγRIIB on B cells and downmodulation of the activating FcγRI on CD14lowCD16+ inflammatory 
monocytes was stronger after 2 weeks as compared to 4-8 weeks in most patients investigated 
suggesting that a single treatment course of IVIG does not lead to sustained restoration of FcγR 
expression levels in patients with CIDP. 
There are several limitations to our study. First, due to the relatively small number of patients 
and the high response rate to IVIG therapy, patients were not stratified for disease severity and 
treatment response. Second, we did not monitor FcγR levels beyond 8 weeks following therapy. 
As mentioned above, repeated infusions of IVIG are generally necessary to maintain a clinical 
benefit [192, 290] and it is tempting to speculate that FcγR expression levels might return to pre-
treatment levels beyond an observation period of 8 weeks. Third, low cell frequencies precluded 
the analysis of potentially important cell subsets such as DCs and neutrophils. Nevertheless, our 
findings should provide an incentive to conduct larger prospective investigations to examine 
FcγR expression in leukocyte subsets of patients with CIDP to evaluate the applicability of 
FcγR expression as a biomarker for disease progression and treatment response. 
Our data support the notion that modulating FcgR expression represents an attractive target 
for immune modulation. Numerous studies suggest that attempts should be made to develop 
therapeutics, such as antibodies which specifically block activating FcgRs, and test their clinical 
efficacy for the treatment autoimmune disease [291-293].
In addition to the requirement of IgG-Fc and FcgRIIB for the clinical efficacy of IVIG in 
several autoimmune disease models [139, 158], a small quantity of sialic acid containing 
IgG-Fc was found to mediate protection in a mouse model of arthritis [133, 165]. Subsequent 
studies implicated a protective mechanism involving the inhibitory Fc receptor (FcγRIIB) and 
the C-type lectin SIGNR1 (CD209b) or its human ortholog DC-SIGN (CD209) [161, 294]. 
Signaling downstream of DC-SIGN was found to induce IL-33 which in turn induces IL-4 in 
basophils leading to the upregulation of FcγRIIB on macrophages [161]. Although the relevance 
of DC-SIGN (or SIGNR1) for the initiation of a sialic-acid specific response is supported by 
several studies [139, 161, 165, 294], it remains unclear whether direct binding of Fc-linked 
sialic acid to these receptors [136] is the initial step as no binding of IgG-Fc (independent of its 
glycosylation) to DC-SIGN was detected by others [138]. Also, conflicting data exist about the 
absolute requirement of sialic acid [166, 167, 295]. However, these studies rose the question to 
which extent IgG-Fc sialylation is regulated in health and disease and which consequences it 
has for antibody functionality. 
We found that patients with CIDP show higher levels of IgG-Fc N-glycans lacking terminal 
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galactose and sialic acid residues as compared to demographically matched healthy individuals. 
Furthermore, increased levels of Fc-sialylation in CIDP sera were associated with clinical 
disease remission in both placebo- and IVIG-treated patients. IgG-Fc sialylation led to reduced 
CDC, providing a functional rationale for the observed disease-related changes. 
IgG-Fc galactose content has long been known to be affected by various pathologic conditions. 
Early observations indicating that the amount of galactosylated IgG is negatively correlated 
with RA and primary osteoarthritis [78] were later confirmed for other autoimmune diseases 
such as Crohn`s disease, SLE and Ankylosing spondylitis [127, 128]. Also, loss of galactose 
on anti-citrullinated protein antibodies precedes the development of RA [296] and the 
extent of pregnancy-induced spontaneous remission of RA correlates with an increase of 
IgG galactosylation [297, 298]. In healthy individuals, the amount of circulating IgG-G0 
antibodies increases with age [299] and decreases during pregnancy followed by an increase 
to pre-pregnancy levels post partum [298]. Additionally, correlation of increased IgG-G0 with 
infections such as HIV-1 [129, 130], infectious endocarditis [128], and hepatitis-C infection 
accompanied by fibrosis and cirrhosis [131] suggests regulation of IgG-Fc galactosylation 
during an ongoing immune response. While the aforementioned studies narrowed the focus 
on the presence or absence of galactose, not the lack of galactose residues themselves but 
rather the concomitant absence of terminal sialic acid may be responsible for the enhanced 
inflammatory activity exerted by aglycosylated glycoforms. Supporting this argumentation, 
increased IgG-Fc sialylation was found to be positively correlated with disease remission of RA 
[298], Wegener`s granulomatosis [300] and CIDP (this study and [301]). Our data suggest that 
IVIG treatment and spontaneous disease remission is associated with an increase of patient-
derived IgG-Fc sialylated antibodies. In CIDP, the clinical efficacy of plasma exchange therapy 
and C3d deposition in patient biopsies on Schwann cells and compact myelin indicates that the 
complement system may play an important role for mediating peripheral nerve damage [181, 
203]. These data suggest that increased IgG-Fc sialylation of pathologic autoantibodies could 
reduce their potency to activate the complement system resulting in reduced immune-mediated 
tissue damage and clinical disease remission. 
Both Fc-receptor dependent (ADCC) and complement dependent (CDC) cytotoxic properties 
of antibodies have been shown to require the presence of the IgG-Fc glycan [114, 302]. 
Consequentially, it is not surprising that also the composition of the glycan impacts antibody 
functionality. From the three variable glycans fucose, galactose and sialic acid, absence of 
fucose has been shown to significantly enhance ADCC [92]. Human sialylated antibodies show 
a reduced binding to murine FcgRs [133] and were reported to convey reduced ADCC [134]. 
We could not find changes in human FcgR binding properties for both sialic acid enriched Fc 
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or tetra-sialylated Rituximab, a humanized IgG1 antibody. In accordance, also ADCC was not 
affected. Previous studies [134] did not distinguish between Fc and Fab sialylation, which may 
provide an explanation for the discrepancy as Fab glycosylation can influence antigen binding 
properties [72] which may influence ADCC independent of the Fc glycan structure. Antibodies 
lacking galactose have been shown to depend on Fc-receptors for their in vivo functionality 
[116] and increased pathogenicity of agalactosylated antibodies was found for murine IgG1 but 
not IgG2a autoantibodies indicating subclass-specific effects of galactosylation [303]. Initial 
studies indicated that lack of galactose allows binding of mannose-binding lectin (MBL), the 
initiator of the lectin pathway of the complement system [115]. However, MBL polymorphisms 
were not found to be associated with RA [304] or pregnancy-induced remission [305] and animal 
studies could also not find a role of MBL and complement for the functionality of agalactosylated 
antibodies in vivo [116, 303]. In accordance with previous data [116], we show that aside of the 
increased affinity for MBL, removal of galactose markedly reduces the affinity for C1q. De-
galactosylated and sialylated antibodies displayed a similar reduction in C1q binding indicating 
that not only the presence of galactose but its location as a terminal sugar on the glycan is 
essential for increased binding. This is in sharp contrast to what was found for FcgRIIB binding 
of IgG1-Fc, which was not influenced by the presence or absence of terminal galactose [84] 
indicating that the structural binding requirements for FcgRs and C1q are different. Of note, data 
acquired in murine models have to be interpreted with caution concerning their transferability 
to humans as binding of C1q to human IgG1 was shown to have distinct requirements from its 
murine ortholog IgG2b [306]. For human IgG1, four spatially close sites on the surface of the 
antibody, D270, K322, P329, and P331, were shown to constitute the C1q binding epicenter 
[306]. However, most of the aforementioned sites are conserved in human IgG isotypes that 
are deficient in C1q binding and it has therefore been suggested that the composition of the 
N-glycan and the hinge region of the antibody might be critical for the antibodies’ conformation 
and its ability to bind C1q [83, 306]. Chrystal structures of differentially glycosylated Fc permit 
at least two possible explanations how the IgG-Fc glycan structure may influence Fc structure 
and function. First, removal of terminal galactose [85] or addition of sialic acid on top of 
galactose [137] both were reported to favor a so-called “closed confirmation” (minimal C2-C2 
domain distance) in contrast to an “open confirmation” (maximal C2-C2 domain distance) as 
found for fully galactosylated antibodies [85]. Second, tetra-sialylated antibodies were reported 
to exhibit increased conformational flexibility [137, 307]. Both a “closed confirmation” and a 
less-well defined structure may disfavor C1q binding. Crystal structures of the C1q globular 
head and galactosylated, de-galactosylated and tetra-sialylated IgG would be required in order 
to clarify how the glycan structure influences C1q binding. An indication for the relevance of 
C1q in human autoimmune diseases is given by the finding that polymorphisms of C1q leading 
to increased C1q serum levels are associated with the risk to develop RA [308] and classical 
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complement pathway activity correlates with disease activity in multifocal motor neuropathy 
[309]. An important consideration for antibody-mediated autoimmunity is that complement 
activation does not only result in cytotoxicity but generates potent inflammatory mediators. 
Amongst them, proteolytic activation of the complement proteins C3 and C5 results in the 
anaphylatoxins C3a and C5a which were implicated in a long list of pathologic conditions 
including RA and SLE [310]. Anaphylatoxins are potent regulators of innate and adaptive 
immune responses by acting on a wide range of cells and tissues via the interaction with their 
G-protein coupled receptors [311]. For example C3a and C5a are involved in T cell activation 
and differentiation [312-314] DC homing [315] and vascular permeability [316]. Complement 
activation also promotes the initiation of an adaptive immune response by opsonization of cells 
and pathogens. For example, C1q can be directly recognized by C1q receptors (CD35, CR1 
and CD93, C1qRp) and complement-activation associated C3 cleavage products (iC3b) can be 
recognized by CD11b/CD18 (CR3) amongst others [317, 318]. These receptors are expressed on 
various cell types including DCs and monocytes/macrophages [318-321] where they contribute 
to the phagocytosis of opsonized cells or bacteria and play an essential role for the removal of 
apoptotic cells [318, 320, 322]. Increased IgG sialylation may therefore also influence the extent 
of antigen presentation to B and T cells and their subsequent development in antibody-secreting 
plasma cells or effector T cells. It is also worth mentioning that the presence of galactose on the 
IgG-Fc glycan may mediate complement-inhibitory effects by a mechanism involving Dectin-1 
and FcγRIIB dependent inhibition of C5a receptor signaling [132], highlighting the complexity 
of complement-regulatory mechanisms influenced by the IgG-Fc glycan. It would be interesting 
to investigate if the presence of sialic acid in addition to galactose still allows this signaling 
pathway to take place. This would result in sialylated antibodies having both low intrinsic CDC 
activity and at the same time reduce pro-inflammatory signaling by C5a.
In CIDP, autoantibodies, complement, T cells, and myeloid cells are currently thought to be 
involved in mediating peripheral nerve demyelination [181]. In such a scenario an unknown 
trigger would initiate the development of peripheral nerve specific autoantibodies leading to 
nerve destruction by the complement system and myeloid cells. The inflammatory milieu would 
then facilitate autoantigen presentation by DCs/myeloid cells supporting the development of 
further pathologic autoantibodies and potentially also autoantigen-specific T cells. De-regulated 
FcgR expression and IgG-Fc glycosylation could therefore predispose for the development 
of autoimmunity but also amplify and sustain the disease. The identified FcγR-independent 
mechanism by which Fc-sialylated glycovariants limit pro-inflammatory IgG effector function 
might complement immunomodulatory effects of IVIG associated with upregulation of the 
inhibitory FcγRIIB  [139, 157, 158, 161] and supports the development of strategies that target 
increased Fc-sialylation for the treatment of autoimmune diseases [323]. 
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The anti-inflammatory properties of IVIG have been extensively studied in murine models of 
antibody-mediated autoimmunity most of which indicated that the Fc part of IgG conveys the 
immunosuppressive properties [139, 158, 165]. IVIG has been previously reported to also reduce 
disease severity of EAE, an animal model for T cell mediated autoimmune neuroinflammation 
[253, 324, 325]. We aimed to investigate the structural requirements of IgG to exert its protective 
function. EAE is induced by subcutaneous immunization with MOG35-55 peptide emulsified in 
CFA, resulting in a strong inflammatory response and the generation of autoantigen-specific 
CD4+ T cells. Confirming published data [246], IVIG was found to be required continuously 
and at high dose in order to protect from EAE development. The most frequently reported 
requirement for IVIG`s protective action in murine models of autoimmunity is the presence of 
the inhibitory FcgR, FcgRIIB [139, 158]. Activating and inhibitory FcgRs have been implicated 
in regulating EAE development [326], further supporting a role for FcgRIIB. However, we were 
not able to reproduce previous data showing an increased susceptibility of FcgRIIB knockout 
mice [326]. In addition, IVIG treatment was still able to reduce disease severity in the absence 
of FcgRIIB although to a lesser extent as seen in B6 wt mice. This may be due to FcgRIIB 
flanking regions, which are insufficiently backcrossed and harbor autoimmune susceptibility 
genes [327]. Increased inflammation may hamper the efficacy of IVIG and require even higher 
dosage for complete protection. In line with that, the dependency on FcgRIIB can be overcome 
by increasing IVIG dose to 2.5 g/kg in experimental ITP [287]. These findings suggested that a 
novel, FcgRIIB-independent mechanism is responsible for IVIG mediated protection in EAE. To 
further test this hypothesis, digestion of IVIG with Ide-S, an enzyme that specifically removes 
the Fc part of IgG was used to generate F(ab’)2 fragments. We found that F(ab’)2 fragments 
were as protective as IVIG. This is particularly surprising as the in vivo half-life of F(ab’)2 can 
be expected to be lower than that of IgG because murine FcRn binds to human IgG [328] which 
significantly increases its half-life [329]. It can therefore be assumed that the total dose of IVIG 
(IgG) in circulation is accumulating more than F(ab’)2. 
If IVIG treatment was stopped, the first EAE symptoms developed around 6 days later. A 
combination of several factors could account for this observation. First, the circulating antibody 
concentration could remain at sufficiently high levels for several days and remain protective. 
Second, it may simply take several days until newly starting demyelination progressed to cause 
paralysis. Third, T cells may be primed only after interruption of IVIG treatment and require 
several days to mount a full-blown adaptive immune response. Because EAE is an established 
model of T cell mediated autoimmunity, the latter was investigated by adoptively transferring 
splenocytes from CFA + MOG35-55 immunized mice either treated or not treated with IVIG into 
naïve recipients. Before transfer, cells were re-stimulated with MOG35-55 peptide and IL-23 to 
promote their inflammatory properties [330, 331]. Both mice treated and not treated with IVIG 
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were able to transfer the disease to naïve mice suggesting that autoantigen-specific T cells are 
generated under both conditions. To investigate if IVIG can inhibit primed, MOG specific T 
cells, we adoptively transferred in vitro re-stimulated splenocytes from MOG-specific TCR-
transgenic mice [252] into naïve recipients and treated with IVIG. Again, treatment was not 
protective indicating that once T cells have been primed, IVIG cannot protect from disease 
development. 
A polyclonal antibody preparation like IVIG contains an almost unlimited number of binding 
partners, which could be relevant for the protective mechanism. One simple explanation 
would be that F(ab’)2 fragments prevent adjuvant (CFA) mediated inflammation. Supporting 
this hypothesis, IVIG was found to contain antibodies recognizing the active component of 
CFA, Mycobacterium tuberculosis [332]. In addition, recognition of soluble mediators or 
cell surface molecules can be envisaged to provide an important contribution. Comparison 
of naïve, CFA + PBS and CFA + MOG35-55 immunized animals showed that the main effect 
seen upon immunization is mediated by the adjuvant as both groups behaved very similar 
in all parameters analyzed. Also, irrespective of F(ab’)2 treatment, both CFA + PBS or 
CFA + MOG35-55 immunized animals developed comparable splenomegaly. To get an insight, 
we  performed in-depth leukocyte profiling following CFA + MOG35-55 immunization and 
F(ab’)2 treatment. It has recently been shown that both IVIG and F(ab’)2 can reduce the number 
of cytokine-producing T cells in EAE [333]. The proposed mechanism involved an expansion 
of Tregs cells and prevention of T cell egress from lymph nodes. We could confirm largely 
reduced frequencies and total numbers of IFN-g, IL-17 or GM-CSF producing CD4+ T cells 
in the spleen. However, although the frequency of Tregs cells was increased in the spleen, 
it was reduced in dLNs and remained unchanged in both compartments if total cell numbers 
were taken into account. Increased numbers of effector T cells in immunized, PBS treated 
animals were rather responsible for the relatively increased frequency of Tregs in F(ab’)2 treated 
animals. This argues against an active, F(ab’)2 mediated expansion of Tregs. We hypothesized 
that alterations in cells of the innate immune system underlie the variations seen in CD4+ T cell 
activation. The most striking observation in F(ab’)2 treated mice was a marked reduction of 
neutrophil expansion in spleen and dLNs. Neutrophils have been shown to play an important 
role during EAE disease initiation and serve as a source of pro-inflammatory cytokines in the 
circulation and during neuroinflammation in the CNS [334]. Importantly, neutrophil depletion 
can prevent EAE disease despite MOG-specific T cell priming takes place [334]. IVIG was 
shown to contain SIGLEC-9 specific autoantibodies which can induce apoptosis in human 
neutrophils [168, 335]. It is tempting to speculate that F(ab’)2 can similarly induce cell death 
of murine neutrophils [336], thereby limiting the availability of pro-inflammatory constituents 
that mediate DC/APC maturation for subsequent T cell activation [334]. Direct inhibition of 
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inflammatory mediators is another potential mechanism of IVIG efficacy [148-150]. 
More work is needed to define the mechanism responsible for reduced EAE pathology in F(ab’)2 
treated animals. So far, our data suggest that less activation of innate immune cells underlies 
reduced T cell activation. Whether F(ab’)2 leads to apoptosis of neutrophils, blocks the action 
of inflammatory mediators, inhibits leukocyte migration or employs yet another mechanism for 
its therapeutic efficacy will be the matter of future investigations.
Concluding remarks
More than 30 years after the first use of IVIG for the treatment of autoimmunity, the number 
of pathological conditions found to be treatable with this agent steadily increases. The success 
of IVIG urgently demands for a better understanding of the underlying mechanisms of action. 
However, over 13 000 scientific publications later, our picture is still incomplete. Because a 
high dose of IVIG is required for its efficacy, it is conceivable that a rare constituent is the active 
component. As such, sialylated Fc is an attractive target considering its anti-inflammatory 
properties in several animal models. Efforts are currently being made to implement it for 
clinical use [241, 247]. Alternatively, immunomodulation may be mediated by one or several 
rare antibody specificities. However, the most consistent finding in IVIG research seems to be 
that different human autoimmune diseases or animal models lead to different results concerning 
both structural requirements of IVIG (IgG, Fab, Fc, Fc-glycan) and the relevance of specific 
host factors (e.g. FcgRIIB, DC-SIGN). Although unsatisfactory at first sight, this could actually 
reflect IVIG’s capability to modulate disease activity in a multitude of different autoimmune 
disease conditions. Therefore, it seems unlikely that IVIG can be replaced with a single drug 
which could recapitulate all aspect of its clinical efficacy. The success of Fc fragments in ITP 
unequivocally demonstrated the dispensability of Fab polyclonality. Still, this does not exclude 
a potential involvement in other diseases. In line with that, we could show that T cell mediated 
autoimmunity in mice can be successfully prevented by F(ab’)2 fragments. Additionally, we 
describe that IgG-Fc sialylation is associated with autoimmune-disease remission and results in 
reduced complement activation. Based on this, a novel treatment approach could be envisaged 
in which IgG-Fc sialylation is actively stimulated in patients affected by antibody-mediated 
autoimmune disease [323]. 
IgG is long known for its pro-inflammatory effector functions essential for the defense of our 
body. Considered paradoxical in the beginning, it became obvious that IgG is also a modulator 
of the immune system contributing to the maintenance of immune tolerance and homeostasis. 
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4. Human subjects and Methods
4.1 FcgR expression analysis in human PBMC
4.1.1 Human subjects
Patients with CIDP (n = 24) and healthy controls matched by age and gender (n = 19) were 
recruited between 2010 and 2013 at the Department of Neurology, University of Marburg, 
Germany (table 4.1). All patients fulfilled the EFNS/PNS diagnostic criteria for CIDP. They 
were prospectively followed during IVIG therapy (2 g/kg over 5 days) using the modified 
Rankin disability scale to monitor clinical treatment response [157, 238]. Improvement in the 
modified Ranking scale within 4 weeks after IVIG treatment was defined as a positive treatment 
response. Patients did not receive IVIG therapy or immunosuppressive treatment including 
corticosteroids before study entry. PBMC samples were collected at each visit and obtained 
before, 2 weeks and 4-8 weeks following treatment with IVIG. The University’s IRB approved 
the study according to the Declaration of Helsinki, GCP and German law (IRB file reference: 
46/00). 
 
Demographic an clinical characteristics of CIDP patients and their controls 
 
 CIDP n=24 Controls n=19 
Age 
(Years ± SD; range) 
59.0 ± 9.4 
(36  72) 
58.7 ± 9.1 
(34  74) 
Duration of symptoms 
(Years ± SD; range) 
0.5 ± 0.4 
(0.1  2.0) 
N/A 
Male to female ratio 3 5 
Fulfilling modified AAN criteria, n; % 24; 100 N/A 
Fulfilling EFNS/PNS criteria, n; % 24; 100 N/A 
Clinical course  N/A 
 RR1), n; % 8; 33.3 - 
 PP2), n; % 14; 58.3 - 
 Monophasic3), n; % 2; 8.3 - 
CIDP subtype4)  N/A 
 CIDP-I, n; % 16; 66.7 - 
 CIDP-MGUS, n; % 2; 8.3 - 
 DADS-I, n; % 2; 8.3 - 
 MADSAM, n; % 4; 16.6 - 
Treatment response5), n; % 21; 87.5 N/A 
 
1) RR – relapsing-remitting 
2) PP – primary progressive 
3) but no Guillain-Barré syndrome 
4) MGUS – monoclonal gammopathy of uncertain significance; DADS – Distal acquired 
demyelinating sensory polyneuropathy; MADSAM – Multifocal acquired demyelinating 
sensory-motor polyneuropathy 
5) defined as  1point decrease in the modified Rankin’ scale 
 
Table 4.1 Demographic and clinical characteristics of CIDP patients and their controls
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4.1.2 Flow cytometry analysis of human PBMC
Fluorochrome labeled antibodies were purchased from Biolegend (CD3-PE-Cy5 (clone HIT3a), 
HLA-DR-Pacific Blue (L243), CD19-AlexaFluor700 (HIB19), CD64-APC-Cy7 (10.1)), BD 
Pharmingen (CD11c-PE-Cy7 (B-Ly6), CD27-PE (M-T271)), Stem Cell Technologies (CD32A-
FITC (IV.3)) eBioscience (CD16-e-fluor605 (eBioCB16), CD123-PerCPCy5.5 (6H6)), 
Invitrogen (CD14-QDot655 (TüK4), CD56-PE-Texas-Red (MEM-188)). Miltenyi (BDCA-
1-PE (AD5-14H12), BDCA-3-PE (AD5-(8E7))  The CD32B (FcgRIIB) specific monoclonal 
antibody clone 2B6 was in-house purified and coupled to Alexa Fluor 647. Dead cells were 
excluded using Fixable Aqua Dead Cell Stain Kit (Invitrogen). Cells were suspended in PBS 
+ 0.01 % sodium azide (FACS buffer) containing the fluorochrome-labeled antibodies and 
incubated for 30 minutes on ice. Cells were washed, suspended in FACS buffer and acquired 
using BD LSR Fortessa cell analyzer (table 4.2). All analysis was performed with FlowJo 9 
(Tree Star).
Optical configuration of BD SLR Fortessa
Laser Mirror Filter Intended dye(s)
735LP 800/50 Qdot800, BV785
685LP 710/50 Qdot705, BV711
640LP 670/30 Qdot 655, eFluor 650nc, BV650
600LP 610/20 Qdot605, eFluor 605nc, BV605
505LP 525/50 AmCyan, Aqua L/D stain, Pacific Orange, BV510
450/50 Pacific Blue, V450, BV421, Cell Trace Violet
635LP 690/50 PerCP, PerCP-Cy5.5
505LP 525/50 FITC, Alexa 488, GFP
488/10 SSC
750LP 780/60 PE-Cy7
685LP 710/50 PE-Cy5.5
635LP 670/30 PE-Cy5, 7aad
600LP 610/20 PE-Texas Red, mCherry
582/15 PE, DsRED, PKH26
750LP 780/60 APC-Cy7, APC-H7, APC-Alexa750, Near IR-L/D stain
685LP 730/45 AlexaFluor 700
670/30 APC, Alexa 647, TO-PRO-3
Optical configuration of BD FACS Canto-II
Laser Mirror Filter Intended dye(s)
502LP 510/50 AmCyan, Aqua L/D stain
450/50 Pacific Blue, V450, BV421, Cell Trace Violet
735LP 780/60 PE-Cy7
655LP 670LP PerCP, PerCP-Cy5.5, 7aad
556LP 585/42 PE, DsRED, PKH26
502LP 530/30 FITC, Alexa 488, GFP
488/10 SSC
735LP 780/60 APC-Cy7, APC-H7, APC-Alexa750, Near IR-L/D stain
685LP 660/20 APC, Alexa 647, TO-PRO-3
Violet (405 nm)
Violet (405 nm)
Blue (488 nm)
Red (640 nm)
Blue (488 nm)
Yellow/Green (561 nm)
Red (640 nm)
Table 4.2 Optical configuration of flow cytometers
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4.1.2.1 Identification of naïve and memory B cells
B cells were identified using the B cell specific molecule CD19 and removal of contaminating 
cells by gating out cells expressing CD14, CD16, CD64, CD3 and CD56, which are all known 
to be absent on B cells. Subsequently, naïve and memory B cells were identified based on the 
expression of CD27, which is a memory B cell specific cell surfase protein(figure 4.1) [337]. 
4.1.2.2 Identification of monocytes and monocyte subsets
Monocytes were identified as being CD11c and MHC class II (MHC-II) positive and CD19 
negative and functionally distinct monocyte subsets were distinguished based on their expression 
of CD14 and CD16 (figure 4.2) [338, 339].
Figure 4.1 B cell gating strategy. 
PBMC were stained with fluorescently labelled antibodies followed and analysed by flow cytometry. 
An exemplary gating is shown starting. Gates are indicated in magenta. B cells were identified by 
sequentially gating on single, living, CD19 positive and CD14 as well as CD16, CD64, CD56 and 
CD3 negative cells. Finally, naïve and memory B cells were identified using CD27 staining.
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Figure 4.2 Monocyte cell gating strategy. 
Single, living cells were gated as shown in figure 4.1. Monocytes were identified by their co-
expression of CD11c and MHC-II while being negative for CD19. Finally, monocyte subsets 
were identified by their CD14 and CD16 expression pattern. 
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4.2 IgG-Fc glycosylation analysis
4.2.1 Human subjects
Samples and clinical data were collected during a randomized placebo-controlled trial (ICE 
trial) testing the efficacy of intravenous injection of 10 % caprylate-chromatography purified 
immune globulin (IGIV-C, Gamunex; referred to as IVIG) in patients with CIDP [192]. Patients 
received either IVIG (2 g/kg body weight initially, 1 g/kg body weight every 3 weeks thereafter) 
or 0.1% albumin (placebo) were followed over 24 weeks [192]. Post-treatment samples were 
taken 2 weeks after the last infusion. Disease remission was defined as improvement in the 
adjusted INCAT score after 24 weeks and was observed in 32 of 59 (54%) patients treated 
with IVIG and 12 of 58 (21%) patients who received placebo [192].  The predicted rate of 
improvement during treatment with placebo in the ICE trial was 15% [192] based on previous 
data obtained in randomized controlled treatment trials in CIDP patients.  
An additional cohort of patients was recruited between 2010 and 2013 at the Department of 
Neurology, University of Marburg, Germany (table 4.3). All patients fulfilled the EFNS/PNS 
diagnostic criteria for CIDP. Patients received IVIG (2 g/kg body weight initially and 1 g/kg 
body weight for maintenance therapy) for at least 2 months. Post-treatment samples were taken 
3 - 5 weeks following the last infusion of IVIG (mean ± SD: 4 ± 0.6). Similar to the ICE trial 
[192], a clinical response to IVIG was defined as improvement in the adjusted INCAT score and 
observed in 31/33 (94 %) patients. The University’s IRB approved the study according to the 
Declaration of Helsinki, GCP and German law (IRB file reference: 46/00). 
Number of patients
Age at study entry (Median; range)
Duration of symptoms (years)
Male to female ratio
Fulfilling modified AAN criteria
Fulfilling EFNS/PNS criteria
Clinical course number of patients % of patients
Relapsing-remitting 5 15.1
Primary progressive 26 78.8
Monophasic 2 6.1
CIDP subtype
CIDP 25 75.8
CIDP-MGUS 0 0
DADS 3 9.1
MADSAM 5 15.2
Treatment response 31 94
100%
33
62; 32 - 79
< 1 - 15
22:11
94%
Table 4.3 Demographic and clinical characteristics of “Marburg cohort “ CIDP patients 
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4.2.2 Reagents 
RPMI-1640, DMEM, Penicillin-Streptomycin (P/S), pooled human serum, TO-PRO-3 Stain, 
LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit, LIVE/DEAD Fixable Aqua Dead Cell Stain 
Kit, 1-StepTM Ultra TMB-ELISA Substrate Solution and CAPTURESELECT IgG-CH1 PRO 
Affinity Matrix were purchased from Life Technologies (Zug, Switzerland). Fetal calf serum 
(FCS) was purchased from BIOCHROM AG. (Berlin, Germany). Recombinant human IL-2 was 
purchased from PeproTech EC Ltd. (London, UK). PKH26 Red Fluorescent Cell Linker Kit and 
was purchased from SIGMA-ALDRICH (Buchs, Switzerland). Ficoll- Paque was purchased 
from GE Healthcare. Accutase was purchased from Stemcell Technologies (Grenoble, France). 
MACS NK Cell Isolation Kit-II (negative selection) and B Cell Isolation Kit (CD19 positive 
selection) were purchased from Miltenyi Biotech (Bergisch Gladbach, Germany). Human 
serum complement and C5 depleted human serum were purchased from TECOmedical Group 
(Sissach, Switzerland). EZ- Link NHS-PEG12-Biotin was purchased from Thermo Scientific 
(Rockford, USA). Papain and Nutridoma-SP were purchased from Roche (Basel, Switzerland). 
HiLoad 16/60 Superdex 200 column, HiTrap Protein G HP Columns, StrepTrap HP Columns, 
HisTrap HP columns and Protein G Sepharose 4 Fast Flow were purchased from GE Healthcare 
(Glattbrugg, Switzerland). Ceramic Fluoroapatite (CFT-II, 40 μM) was purchased from Bio-Rad 
(Hercules, CA, USA). Biotinylated lectins (Lens culinaris agglutinin (LCA), Sambucus nigra 
agglutinin (SNA), Erythrina cristagalli lectin (ECL) and Aleuria aurantia lectin (AAL) and 
SNA-Agarose were purchased from Vector Laboratories (Burlingame, USA). Neuraminidase 
was purchased from New England Biolabs (Ontario, Canada). UDP-Galactose, CMP-Sialic 
Acid, β1,4-Galactosidase and Amicon Ultra centrifugal filters were purchased from Merck 
Millipore (Billerica, USA). StarGate cloning and expression system was purchased from IBA 
(Göttingen, Germany). 
4.2.3 Antibodies and streptavidin 
RTX (MabThera) was purchased from Roche (Basel, Switzerland). Monoclonal mouse anti-
human C1q as well as biotinylated anti-human C1q and anti-human-C3c were purchased from 
TECOmedical Group. Anti-human IgG-Fc-HRP was purchased from Sigma-Aldrich (Buchs, 
Switzerland). Anti-CD20- PE-Cy7 was purchased from eBioscience (San Diego, USA). 
Polyclonal rabbit anti- Mouse IgG (H+L)-A488 was purchased from Life Technologies (Zug, 
Switzerland). Streptavidin-FITC and Streptavidin-PE were purchased from Biolegend (San 
Diego, USA).
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4.2.4 Serum IgG quantification 
Serum samples were taken before the initiation of the study (baseline) and 24 weeks (ICE 
trial) or < 7 weeks (Marburg cohort) thereafter, stored at -80 ºC. Total serum IgG levels were 
determined using a commercially available human IgG ELISA (Immundiagnostik, Bensheim, 
Germany) according to the manufacturer’s instructions.
4.2.5 2-AB labeled glycosylation analysis (2-AB HPLC-FL)
Papain digestion and Protein-G sepharose was used to purify IgG-Fc (done as for lectin blotting, 
see 4.2.6). For release of N-Glycans, 110 µg protein samples were dried and suspended at 100 °C 
for 10 min in 20 mM HEPES buffer pH 8.2 containing 1 % SDS. SDS was blocked by NP-40 and 
N-glycans were released by PNGaseF and separated from glycopeptides using a Sep-Pak C18 
cartridge. The carbohydrates contained in the flow-trough were applied to a porous graphitized 
carbon (PGC). Under aqueous conditions, oligosaccharides bind to the PGC cartridge, while 
salts and buffers pass through. Glycans were eluted by 15-100 % Acetonitrile and used for 
2-AB tagging and HPLC-FL analysis. For labeling with 2-Aminobenzamide (2-AB) 100 µl 
of the cyanoborohydride mixture (prepared by adding 6.5 mg of sodium cyanoborohydride in 
200 µl of a 35:65 glacial acetic acid: DMSO mixture) were added to 6 mg of 2-AB reagent, 
vortexed and sonicated to mix thoroughly.  10 µl of 2-AB reagent were added to each sample 
and incubated at 65 °C for 2.5 hours. After 2-AB labeling the samples were purified by passing 
through a Glycoclean S-cartridge (Prozyme) and dried in a speed vac. Analysis of 2-AB labeled 
glycans was performed by HPLC-fluorescence detection (HPLC-FL) using a Dionex DX-600 
HPLC System. Therefore, 2-AB labeled glycans were dissolved in water and separated on a 
Dionex analytical column (Carbo Pac PA 100, 2 × 250 mm) using 100 mM NaOH (0 - 20 min) 
and 100 mM NaOH with 250 mM NaOAc (20 - 80 min) gradients. Glycan release, labeling 
and HPLC-FL was done by Biswa Pronab Choudhury and collegues at Glycobiology Core 
Resources in La Jolla, California.
4.2.6 Fc purification from serum and sample preparation for lectin blotting
Serum was obtained by centrifugation of complete heparinized blood at 5 000 x g for 2 minutes 
and stored at –20 C°. 15 µl serum was diluted to 30 µl with PBS. 30 µl 2-fold concentrated 
papain reaction buffer (0.04 M EDTA + 0.04 M L-Cystein in PBS, pH adjusted to 6.5 with 
2 M NaOH). 3 µl papain were added and samples were incubated for 1 h at 25 °C while 
rotating at 600 rpm. To stop the reaction, 50 µl 10 x protease inhibitor (Roche “Complete”) 
were added. 20 µl Protein G sepharose slurry was washed 3 times with 1 ml PBS (centrifuged 
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at 1500 g for precipitation of beads). 400 µl PBS were added to the papain-treated-serum-PBS-
protease-inhibitor-mix and transferred on the washed beads. To allow binding, samples were 
incubated over night at 4 °C.  For elution, 90 µl 0.1 M glycin at pH 2.7 was added and samples 
were incubated for 3 minutes at 95 °C while rotating at 1000 rpm. Subsequently, samples were 
immediately centrifuged for 5 minutes at 1500 x g at 4 °C. The supernatant was transferred 
to a new tube containing 10 µl Tris buffer at pH 8.8 to neutralize the pH to 7.4. At that stage, 
samples were either stored at −20 °C or immediately used for lectin blotting. 
4.2.7 Lectin blotting and analysis
Fc-linked glycans were analyzed by lectin blotting using biotinylated lectins as previously 
described [133, 165] (LCA, SNA, ECL, AAL). In brief, 12.5 µl purified serum-derived Fc (see 
chapter 4.2.6) was mixed with 37.5 µl PBS and 15 µl 5 × Laemmli buffer (1.5 g SDS, 3.75 
ml 1 M Tris pH6.8, 0.015 g bromphenol blue, 1.16 g DTT, 7.5 ml (9.5 g) glycerol; 15 ml with 
ddH2O) and incubated for 3 minutes at 95 °C. After centrifugation at 16 000 × g, 13 µl (for ECL, 
SNA and AAL) or 7 µl (for LCA) were loaded on a 10 % Polyacrylamide gel. The protein was 
transferred to a nitrocellulose membrane in a semi-dry blotter for 1 hour at 12 V. Membranes 
were blocked for 1 hour with western blocking reagent (Roche) diluted to 1 × in TBS.  Lectins 
were diluted 1:1000 in TBS + 0.1 mM CaCl2, MgCl2 and MnCl2
 and incubated for 1 hour in the dark. After washing 6 times with TBS + 0.1 % Tween20, 
lectin binding was detected using HRP-labeled streptavidin (MABtech) and quantified by 
chemiluminescence using SuperSignal West Pico Chemiluminescent substrate (Pierce) and 
digital detection of the chemiluminescence signal with Fusion FX Spectra (Vilber Lourmat). 
Analysis was performed using Image J (NIH). Signal intensities for each glycan (fucose, 
terminal galactose, and sialic acid) were normalized to the signal obtained for the core glycan 
(mannose) and are expressed as glycan contents relative to a reference serum (signal intensity 
was set to 1).
4.2.7.1 Specific and quantitative detection of individual IgG-Fc glycan residues by lectin-
blotting
Human IgG-Fc obtained by papain digestion and protein-G affinity purification analyzed by 
lectin-blotting using Lens culinaris agglutinin (LCA) recognizing mannose [340], Erythrina 
cristagalli lectin (ECL) recognizing terminal galactose [341], Sambucus nigra agglutinin (SNA) 
recognizing sialic acid [342, 343] and Aleuria aurantia lectin (AAL) recognizing fucose [340]. 
Removal of the IgG-Fc glycan by PNGase-F treatment was used to confirm glycan-dependent 
recognition of IgG-Fc by the lectins. As shown if figure 4.3A, PNGase-F treatment leads to a 
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molecular weight shift due to the loss of the glycan and the shifted lane is no longer recognized 
by lectins, confirming their specificity. Neuraminidase treatment specifically removes sialic acid 
leading to a loss of SNA recognition as well as an increase of ECL signal due to the presence of 
more terminal galactose upon sialic acid removal (figure 4.3A). Because the IgG-Fc content of 
different serum samples varies, we needed to identify the linear range of the lectin signal. All 
lectin signals were linear over the entire relevant range (figure 4.3B).
4.2.8 Purification of Fc, de-sialylated Fc and sialic acid enriched Fc from polyclonal IgG 
Intravenous Immunoglobulin (Pivigen, CSL Behring AG, Bern, Switzerland) was used as 
source of human IgG. 550 mg IgG was incubated in 0.02 M EDTA, 0.02 M L-cysteine in PBS 
at pH 6.5 with 0.8 mg papain for 2 hours at 25 °C. Uncut IgG and papain were separated by 
size exclusion with a HiLoad 16/60 Superdex 200 column and GE Aekta purifier. The fraction 
containing the Fc and Fab fragments was concentrated using Amicon Ultra 15 ml centrifugal 
filters with a molecular weight cut-off of 10 kDa and dialyzed to 5 mM Na-phosphate buffer pH 
7.1. Fab and Fc were separated using a self-packed 50 ml Ceramic Fluoroapatite column (CFT 
Type II, 40 μm) and Äkta purifier (GE Healthcare) [344]. Therefore, 50 mg Fab/Fc protein 
Figure 4.3 Specific and quantitative detection of IgG-Fc glycan residues by lectin blotting.  
(A) Exemplary lectin-blots of serum derived IgG-Fc. Neuraminidase treatment for removal of sialic 
acid and PNGase F for removal of the entire glycan (arrows indicate the position of the completely 
de-glycosylated Fc) was used to test the specificity of the lectins. (B) Correlation of the amount of 
IgG-Fc loaded with the signal intensity obtained by lectin blotting. 
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 (1 mg per ml CFT material) at a concentration of 5 mg/ml were applied to the column using 5 
mM Na-phosphate buffer pH 7.1 as running buffer. At this phosphate concentration, bot Fc and 
Fab bind to the column. Fc was eluted with 30 mM Na-phosphate buffer pH7.1 (by mixing 10 % 
250 mM Na-phosphate buffer to the 5 mM Na-phosphate buffer). After an increase to 42.5 mM 
Na-phosphate buffer to remove the remaining Fc, Fab was eluted with 155 mM Na-phosphate 
buffer at pH 7.1 (by mixing 60 % 250 mM Na-phosphate buffer to the 5 mM Na-phosphate 
buffer). The column was cleared with 250 mM Na-phosphate buffer at pH 7.1 (figure 4.4).  
For purification of sialic acid enriched Fc, Fc was dialyzed to TBS and CaCl2 was added to a 
final concentration of 0.1 M. Sialic acid enriched Fc was purified from 40 mg Fc by binding 
to 4 ml SNA-Agarose and elution with 0.5 M lactose in TBS as previously described [165]. 
For neuraminidase treatment, Fc was dialyzed to 50 mM sodium citrate pH 6 and incubated 
with one unit neuraminidase per μg Fc for 48 hours at 37 °C. Neuraminidase was removed 
using Protein-G sepharose. For further purification, Fc, de-sialylated Fc and sialic acid enriched 
Fc were cleared from residual Fab using a Captureselect IgG-CH1 pro affinity matrix and re-
applied to a HiLoad 16/60 Superdex 200 column. 
4.2.9 Purification of hu8-18C5 antibody
The hu8-18C5 antibody has been generated by cloning of the 8-18C5 hybridoma-derived 
Igh and Igk variable-region sequences into human IgG1 heavy-chain and kappa light chain 
expression vectors as previously described (21). hu8-18C5 was purified by co-transfecting 
A
60 80 100
0
1000
2000
3000
4000
Fab + Fcuncut IgG
ml
m
AU
0 100 200 300
0
1000
2000
3000
FabFc
ml
m
AU
m
S
/cm
0
5
10
15
20
25
Conductivity (mS/cm)
OD280nm (mAU)
OD254nm (mAU)
OD280nm (mAU)
OD254nm (mAU)
B
4.4 Purification of Fab and Fc from IVIG  
(A) Size-exclusion chromatography profile of papain digested IVIG. The collected fraction 
corresponding to Fab and Fc is indicated with dotted lines. (B) CFT-II column chromatography 
profile. The collected fractions containing Fab and Fc are indicated with dotted lines. The buffer 
conductivity is shown as a dotted grey line.
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the calcium phosphate precipitated expression vectors in HKB-11 cells [345]. After 12 hours 
the medium was exchanged to DMEM containing P/S (50 U/ml) and 1 % Nutridoma-SP. The 
culture supernatant was harvested four days later and antibodies were purified using HiTrap 
Protein G HP columns according to the manufacturer’s instructions using GE Aekta prime 
plus. 
4.2.10 Purification of recombinant glycosyltransferases
For the purification of human sialylatransferase, a plasmid containing the cDNA of human 
ST6Gal-I was purchased from Sino Biological Inc. and the extracellular domain (AA 27 - 
406) was cloned into the pCSG-IBA-144 expression vector using the StarGate cloning system 
according to the manufacturer’s instructions. This yields plasmids encoding for proteins 
containing an N-terminal Twin-Strep-tag and a C-terminal Hexahistidine-tag (figure 4.5A). 
HEK293T cells were cultured under standard cell-culture conditions in DMEM containing 
10 % FCS and P/S (50 U/ml) and transfected with calcium-phosphate precipitated plasmids 
encoding ST6Gal-I. After 12 hours, the medium was replaced with fresh DMEM containing 
10 % FCS and P/S (50 U/ml) and cells were cultured for another 3 days. The cell supernatant 
was harvested and proteins were purified by immobilized metal ion affinity chromatography 
(HisTrap HP columns) and subsequently Strep-Tactin affinity chromatography (Strep-Trap HP 
columns) according to the manufacturer’s instructions using GE Aekta prime plus. 
For the purification of bovine β1-4Gal-T (GenBank ref.: BC120415.1), the cDNA coding for 
amino acids 115 to 402 was synthesized by GeneArt (Life Technologies) (figure 4.5B) [346]. 
Re-cloning, expression and purification was done as described for ST6Gal-I.
A 
 
Amino acid sequence of the expressed human ST6GAL-I protein construct 
 
MASAWSHPQFEKGGGSGGGSGGSAWSHPQFEKSGMKEKKKGSYYDSFKL
QTKEFQVLKSLGKLAMGSDSQSVSSSSTQDPHRGRQTLGSLRGLAKAKP
EASFQVWNKDSSSKNLIPRLQKIWKNYLSMNKYKVSYKGPGPGIKFSAE
ALRCHLRDHVNVSMVEVTDFPFNTSEWEGYLPKESIRTKAGPWGRCAV
VSSAGSLKSSQLGREIDDHDAVLRFNGAPTANFQQDVGTKTTIRLMNSQL
VTTEKRFLKDSLYNEGILIVWDPSVYHSDIPKWYQNPDYNFFNNYKTYRK
LHPNQPFYILKPQMPWELWDILQEISPEEIQPNPPSSGMLGIIIMMTLCDQ
VDIYEFLPSKRKTDVCYYYQKFFDSACTMGAYHPLLYEKNLVKHLNQGT
DEDIYLLGKATLPGFRTIHCGSAHHHHHH 
 
B 
 
Amino acid sequence of expressed bovine β1-4Gal-T protein construct 
 
MASAWSHPQFEKGGGSGGGSGGSAWSHPQFEKSGMGSNLTSAPVPSTTTRS
LTACPEESPLLVGPMLIEFNIPVDLKLVEQQNPKVKLGGRYTPMDCISPH
KVAIIIPFRNRQEHLKYWLYYLHPILQRQQLDYGIYVINQAGESMFNRAK
LLNVGFKEALKDYDYNCFVFSDVDLIPMNDHNTYRCFSQPRHISVAMDK
FGFSLPYVQYFGGVSALSKQQFLSINGFPNNYWGWGGEDDDIYNRLAFR
GMSVSRPNAVIGKCRMIRHSRDKKNEPNPQRFDRIAHTKETMLSDGLNS
LTYMVLEVQRYPLYTKITVDIGTPSGSAHHHHHH 
 
 Figure 4.5 (continued on next page)
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4.2.11 Generation of antibody glycovariants
Tetra-sialylated RTX was generated by chemoenzymatic glycoengineering as previously 
described [239] with adequate modifications. Briefly, commercial rituximab (8 mg) was 
incubated with EndoS WT (25 μg) at 37 °C for 1 hour and the completion of deglycosylation 
was confirmed by LC-MS analysis. The deglycosylated antibody was purified using a HiTrap 
protein A column and the eluted fractions were concentrated and buffer exchanged into 1 x 
PBS pH 7.4. The purified Fuc-α1,6-GlcNAc-rituximab (7 mg) and sialylated complex type 
oxazoline (3.5 mg) were incubated with EndoS D233Q (175 μg) at 37 °C in 100 mM Tris pH 
7.4 (500 μL total volume). The reaction progress was monitored using LC-MS analysis and 
complete transfer was achieved in 1.5 hours. The tetra-sialylated rituximab was purified using 
a Hitrap protein A column and was concentrated and buffer exchanged into 1x PBS pH 7.4. 
LC-MS: heavy chain of rituximab with sialylated complex type glycan, M = 51412 Da; found 
(m/z), 51412 (deconvolution data). Enzymatic galactosylation and sialylation were performed 
as previously described [87, 165]. For galactosylation, antibodies were buffer-exchanged to 
0.2 mM MES pH 6.5 and incubated for 24 hours at 37 °C in the presence of 5 μg β1-4 Gal-T 
per mg antibody, 10 mM UDP-galactose and 20 mM MnCl2. Non-galactosylated antibodies 
(“unmodified”) were treated the same way but without addition of UDP-galactose and β1-4 
Gal-T. After buffer exchange to 25 mM MOPS 100 mM KCl (pH 7.2) galactosylated antibodies 
were sialylated by addition of 50 μg ST6Gal-I per mg antibody and CMP-sialic acid at a final 
concentration of 1.5 mM. The reaction was incubated for 24 hours at 37 °C. Non-sialylated 
antibodies (“unmodified” and “galactosylated”) were treated the same way but without the 
addition of CMP-sialic acid and ST6Gal-I. All antibodies were buffer-exchanged to TBS. To 
enrich for antibodies containing sialic acid, sambucus nigra agglutinin (SNA) lectin affinity 
chromatography was performed as previously described [165]. For de-galactosylation, RTX 
or hu8-18C5 was dialyzed to 50 mM sodium phosphate pH 6.0 and incubated 6 hours at room 
temperature and 1 hour at 37 °C in the presence of 30 mU β1,4-galactosidase per mg antibody. 
Finally, all antibodies were purified using protein-G sepharose 4 fast flow according to the 
manufacturer`s instruction, dialyzed to PBS and sterilized by 0.2 μM filtration. 
Figure 4.5 Amino acid sequence of expressed ST6Gal-I and 
β1-4Gal-T protein constructs (continued)
The extracellular domains of human ST6GAL-1 (A) and bovine β1-
4Gal-T (B) were cloned into separate pCSG-IBA144 vectors. In silico 
sequence translation of the resultant open reading frame shows the 
N-terminal Twin-Strep-II tag followed by the respective extracellular 
domain (depicted in bold) and a C-terminal hexa-HIS tag. 
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SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and silver staining were performed to 
test antibody integrity and purity and lectin-blotting was used to confirm glycan modifications. 
4.2.12 FcγR binding assay 
RTX and tetra-sialylated RTX were biotinylated using EZ-Link NHS-PEG12-Biotin according 
to the manufacturer’s recommendations. 1 × 105 CHO cells stably expressing none or one of 
the human FcγRs [240] were incubated for 30 minutes on ice in the presence of RTX or tetra-
sialylated RTX. Cells were washed twice with PBS and incubated for 30 min with streptavidin-
FITC for detection of binding and LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit for dead 
cell exclusion. After washing twice with PBS, cells were acquired using BD FACS Canto- II 
(see table 4.2 for optical configuration) and analyzed with FlowJo (Tree Star). 
4.2.13 Antibody-dependent cell-mediated cytotoxicity (ADCC) assay
ADCC assay was performed as previously described [347]. Human peripheral blood 
mononuclear cells (PBMC) were isolated from buffy-coats using Ficoll gradient centrifugation. 
NK cells were negatively selected using MACS NK cell isolation kit and B cells were positively 
selected using MACS CD19 positive selection kit. Both cells were cultured over night in RPMI 
supplemented with P/S (50 U/ml) and 5 % heat-inactivated pooled human serum in 24-well 
plates at 5 × 106 cells per well. NK cell medium was additionally supplemented with 100 
IU IL-2. On the next day, B cells were stained with PKH26 according to the manufacturer’s 
recommendation. 1 × 104 B cells were incubated in the presence of autologous NK cells (1 × 
103 to 1 × 105) and RTX (0.1 μg/ml to 1 ng/ml) in RPMI supplemented with P/S (50 U/ml), 5 
% heat-inactivated pooled human serum and 100 IU IL-2 in 96-well round-bottom plates for 18 
hours in a humidified incubator at 37 °C and 5 %. For cell death assessment TO-PRO-3 stain 
was added to a final concentration of 200 nM and cells were acquired using BD FACS Canto-II 
(see table 4.2 for optical configuration) and analyzed with FlowJo (Tree Star). 
4.2.14 Complement-dependent cytotoxicity (CDC) assay 
Raji or Ramos cells were used to assess RTX (anti-CD20)-mediated CDC. Therefore, 7 × 104 
cells were placed in a humidified incubator at 37 °C and 5 % CO2 in RPMI-1640 containing 
P/S (50 U/ml) in 96-well V-bottom plates in the presence or absence of RTX (MabThera, 
Roche) or glycovariants of it. After 30 minutes human serum complement was added to a final 
concentration of 5 % and the incubation was continued for 12 hours. For hu8-18C5- mediated 
CDC 2 × 104 MO3.13 MOG cells were seeded in 96-well flat-bottom plates in DMEM + 
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10 % FCS. On the next day the medium was removed and DMEM containing 15 % serum 
complement with or without hu8-18C5 or a glycovariant of it following incubation for 4 hours 
in a humidified incubator at 37 °C and 5 % CO2. For cell death assessment TO-PRO-3 stain was 
added to a final concentration of 200 nM and cells were analyzed using BD FACS Canto-II (see 
table 4.2 for optical configuration) and analyzed with FlowJo (Tree Star). 
4.2.15 C1q binding assay 
For C1q binding to Raji or Ramos cells, 2 × 105 cells were seeded in RPMI-1640 containing 
1 % C5-depleted human serum in the presence of 10 μg/ml RTX or RTX glycovariants for 5, 
15, 30, 60 or 120 minutes in a humidified incubator at 37 °C and 5 % CO2. For C1q binding 
to MO3.13 MOG cells, cells were detached using accutase and 1 × 105 cells were seeded in 
DMEM containing 1 % C5-depleted serum in the presence of 2.5 μg hu8-18C5 or hu8-18C5 
glycovariants for 5, 15, 30, 60 or 120 minutes in a humidified incubator at 37 °C and 5 % CO2. 
C1q binding was detected by staining on ice with biotinylated anti-C1q for 1 hour. Cells were 
washed twice with PBS and incubated on ice with streptavidin-PE and LIVE/DEAD Fixable 
Aqua Dead Cell Stain Kit for 25 minutes. After washing twice with PBS samples were acquired 
using BD FACS Canto-II (see table 4.2 for optical configuration) and analyzed with FlowJo 
(Tree Star). 
4.2.16 C3b deposition assay
2 × 105 Raji cells were seeded in RPMI-1640 containing 1 % C5-depleted serum in the presence 
of 10 μg/ml RTX or RTX glycovariants for 5, 15, 30, 60 or 120 minutes in a humidified incubator 
at 37 °C and 5 % CO2. For C3 deposition assessment cells were stained with biotinylated anti-C3c 
for 1 hour on ice. Cells were washed twice with PBS and incubated on ice with streptavidin-PE 
and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit for 25 minutes. After washing twice with 
PBS samples were acquired using BD FACS Canto-II (see table 4.2 for optical configuration) 
and analyzed with FlowJo (Tree Star). 
4.2.17 C1q binding ELISA 
Microtiter plates (Nunc Maxisorp) were coated over night at 4 °C with 0.5 μg Fc, de-sialylated 
Fc or sialic acid enriched Fc in coating buffer (0.05 M sodium carbonate buffer, pH 9). Binding 
efficiency to the plate was examined using anti-human IgG-Fc- HRP as the probe. Wells were 
washed and incubated with human serum complement diluted in PBS containing 0.05 % 
Tween20 (PBS-T) and 1 % BSA for 2 hours at room temperature. After washing with PBS-T 
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wells were incubated for 1 hour with biotinylated anti-C1q, washed with PBS-T and incubated 
for 1 hour with streptavidin- HRP. HRP activity was quantified using incubation TMB-ELISA 
substrate and colorimetric detection at 450 nm. 
4.3 Analysis of IVIG and F(ab’)2 in EAE
4.3.1 Purification of Ide-S
A plasmid containing the cDNA of Ide-S (NCBI Reference Sequence: NP_269065.1) was 
synthesized and cloned into the pMA-T vector invitrogen and subcloned in a modified pET28a 
(GE Healthcare) vector containing an n-terminal deka-HIS tag and a PreScission protease 
cutting site (Ge Healthcare, PreScission protease cutting for HIS tag removal was done). 
MC1060/pWTZ594 e.coli were used for cloning and plasmid amplificatin. The final plasmid 
was transferred into BL21 E.coli (NEB) for protein expression. Bacteria were grown to and 
OD600nm of 0.3-0.4 and expression was induced by addition of 0.1 mM IPTG for 3 hours at 37 
°C. The bacteria pellet was resuspended in PBS containing DNAse (20 µg/ml final, Sigma) 
and 1.6 mM PMSF. Bacteria were lysed by sonication and Ide-S was purified by immobilized 
metal ion affinity chromatography (HisTrap HP columns, GE healthcare) using Äkta prime plus 
(GE healthcare). Successful purification was monitored by SDS-PAGE and coomassie staining. 
Finally, the protein was extensively dialyzed to PBS, sterile filtered through a 0.2 µM filter, 
supplemented with 20 % glycerol and protein concentration was adjusted to 1 mg/ml before 
snap-freezing in liquid nitrogen and storage at −80 °C. 
Figure 4.6: Ide-S amino acid sequence
Ide-S was cloned into the pET28 nHIS vector. The in silico translation of the resultant protein 
is shonw. Amino acids corresponding to the Ide-S are depicted in bold.
AA sequence of the expressed Ide-S protein  
 
 
MHHHHHHHHHHLEVLFQGPSADSFSANQEIRYSEVTPYHVTSVWTKGVTP
PANFTQGEDVFHAPYVANQGWYDITKTFNGKDDLLCGAATAGNMLHW
WFDQNKDQIKRYLEEHPEKQKINFNGEQMFDVKEAIDTKNHQLDSKLFE
YFKEKAFPYLSTKHLGVFPDHVIDMFINGYRLSLTNHGPTPVKEGSKDPR
GGIFDAVFTRGDQSKLLTSRHDFKEKNLKEISDLIKKELTEGKALGLSHT
YANVRINHVINLWGADFDSNGNLKAIYVTDSDSNASIGMKKYFVGVNSAG
KVAISAKEIKEDNIGAQVLGLFTLSTGQDSWNQTN 
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4.3.2 Purification of F(ab’)2 from IVIG
For F(ab’)2 purification from IVIG, 2 mg Ide-S were incubated with 3 ml (300 mg) IVIG at 
room temperature for at least 8 hours (or over night). F(ab’)2 was separated from uncut IgG 
and monomeric Fc using a HiLoad 26/60 Superdex 75 prep grade column (GE Healthcare) and 
Äkta Purifier with PBS as running buffer. The F(ab’)2 containing fraction was concentrated by 
ammonium-sulfate precipitation. Therefore, F(ab’)2 in PBS was mixed with twice the volume 
of saturated ammonium sulfate solution and incubated or 1 hour at room temperature. After 
centrifugation for 30 minutes at 3 000 × g, the supernatant was removed and the precipitate 
resuspended in PBS. F(ab’)2 was extensively dialyzed to PBS and applied to a self-packed 
protein A sepharose (GE-Healthcare) column by gravity flow to remove remaining full-length 
IgG. The column flow-through, containing the F(ab’)2, was concentrated using Amicon Ultra 15 
ml centrifugal filters with a molecular weight cut-off of 10 kDa according to the manufacturers 
instructions to reach a final concentration of 35 to 45 mg/ml. Succesful purification of F(ab’)2 
was confirmed by SDS-PAGE and coomassie staining (figure 4.7B). Finally, the solution was 
sterile filtered through a 0.2 µM filter and stored at 4 °C until use.  
4.7 F(ab’)2 purification
(A) Size-exclusion chromatography profile of Ide-S digested IVIG. The peaks corresponding to 
F(ab’)2 and Fc are indicated. (B) Coomassie stained non-reducing (left) or reducing (right) SDS-
PAGE showing IVIG and purified F(ab’)2 and Fc.
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4.3.3 Purification and biotinylation of anti-mouse FcgRIIB antibody (K9.361)
An antibody specifically recognizing FcgRIIB was purified from K9.361 hybridoma [348] 
(kindly provided by Ulrich Hammerling) supernatant. To do so, hybridoma cells were cultured 
in CELLine culture flasks (BD Bioscience) in PFHM-II medium (Gibco, Life Technologies) 
according to the manufacturers instructions. The antibody-containing cell suspension was 
harvested after 2 weeks and centrifuged three times at 4000 × g to remove cells and debris. 
After filtration through a 0.4 µM filter, antibodies were precipitated by dropwise addition of 
saturated ammonium-sulfate at a temperature of 4 °C. After incubation for 1 hour, the suspenson 
was centrifuged at 4000 × g and the pellet was resuspended in 25 ml PBS. After a second 
precipitation step, the antibody was resuspended in 2.5 ml PBS and de-salted using a de-salting 
column (PD-10 column, GE Healthcare) according to the manufacturers instructions. The 
purified antibody was dialyzed to PBS, sterile-filtered through a 0.2 µM filter and stored at 4 °C. 
For biotinylation, a 20-fold molar excess of EZ-Link NHS-PEG12-Biotin (Life Technologies) 
was added for 4 hours at room temperature followed by dialysis to PBS. 
4.3.4 Genotyping of FcgRIIB-/- mice
The genotype of FcgRIIB-/- mice (kindly provided by Jeffrey V. Ravetch) was confirmed by flow 
cytometry analysis of blood collected from the animal’s tail vain. To do so, red blood cells were 
lysed using RBC lysis buffer (Biolegend) and the cells were stained with anti-CD19-Pacific 
blue (clone 6D5, Biolegend) and in-house purified and biotinylated anti-FcgRIIB [348] (clone 
K9.361). Cells were incubated for 20 minutes at 4 °C and washed once with PBS. For detection 
of K9.361 binding, cells were stained with Streptavidin-FITC (Biolegend). After washing with 
PBS, cells were acquired using BD FACS Canto-II (see table 4.2 for optical configuration) and 
analyzed with FlowJo (Tree Star). 
Heterozygous animals were obtained by crossing FcgRIIB-/- mice with B6 wildtype mice. 
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4.3.5 EAE induction and monitoring of disease  
EAE was induced induced C57BL/6 (B6) mice as previously described [349] with minor 
adaptations. MOG35-55 peptide (MEVGWYRSPFS-RVVHLYRNGK; GenScript) was dissolved 
in PBS to reach a final concentration of 5 mg/ml. 30 ml CFA (Adjuvant complete H37 Ra, Difco 
Laboratories, Detroit, USA) was supplemented with 100 mg dried inactivated mycobacterium 
tuberculosis (M. Tuberculosis Des. H37 Ra, Difco Laboratories, Detroit, USA). On the day 
of immunization, 20 µl (100 µg) peptide solution was supplemented with 80 µl PBS and 
emulsified in 100 µl supplemented CFA (values are given for one mouse; 20 % excess should 
be prepared) by vigorously mixing the solution via transfer in between two syringes connected 
to each other with a Luer-Lock connector for 15 minutes. 6 to 8 weeks old female B6 mice, 
2D2 TCR transgenic mice or FcgRIIB-/- mice were used for immunization. Therefore, mice 
were anesthetized with isoflurane and 100 µl emulsion was injected into the left and right lateral 
abdomen using a 24 G x 1’’ needle. In addition, mice received i.p. injection of 200 ng pertussis 
toxin (pertussis toxin in Glycerol, List Biological Laboratories) on the day of immunization and 
two days thereafter. Mice were monitored daily for general health and disease progression. The 
following scoring system was applied: 
0 - no detectable signs of EAE; 0.5 - Distal limp tail; 1.0 - Complete limp tail; 1.5 - limp tail 
and hind limb weakness; 2.0 - unilateral partial hind limb paralysis; 2.5 - bilateral partial hind 
limb paralysis; 3.0 - complete bilateral hind limb paralysis; 3.5 - complete bilateral hind limb 
paralysis and partial forelimb paralysis; 4.0 - moribund; 5.0 – dead
Mice were euthanized by CO2 inhalation if a disease score of 3 was maintained for more than 
7 days, a disease score of 3.5 was maintained for more than 3 days or disease score of 4 was 
reached. 
Fc
gR
IIB
B6 wt B6 FcgRIIB-/-
CD19 CD19
Fc
gR
IIB
Figure 4.8 Exemplary flow cytometry analysis for FcgRIIB genotyping
Blood from B6 wt or FcgRIIB-/- mice was stained with anti-CD19 and anti-FcgRIIB 
and analyzed by flow cytometry.
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4.3.6 Passive induction of EAE by adoptive cell transfer
Donor mice (B6 or 2D2 TCR transgenic) were actively immunized as described above. On day 
7 post immunization, spleen and draining lymph nodes were harvested and leukocytes purified 
(see below). Cells were restimulated in vitro by cultivation for 2 days at a density of 1 x 107 
cells/ml at 37 °C and 5 % CO2 in 12 cm cell-culture dishes (Greiner)  in RPMI 1640 medium 
(10 ml per dish) supplemented with P/S, 10 ng/ml recombinant IL-23 (eBioscience) and 20 µg/
ml MOG35-55. Recipient mice were sublethally irradiated ad 550 rad one day before i.p. injection 
of 1 x 107 restimulated cells. Disease progression was monitored as described above. 
4.3.7 Lymphocyte isolation from spleen and lymph nodes
Mice were euthanized by CO2 inhalation. Spleen and inguinal lymph nodes were removed 
and mechanically disrupted using scissors. If myeloid cell isolation was aimed, disrupted 
tissues were incubated at 37 °C in 3 ml PBS containing 0.4 mg/ml Collagenase D (Roche) and 
0.1 mg/ml DNase (Sigma) for 30 minutes. The reaction was stopped by adding EDTA to a final 
concentration of 10 mM. Thereafter, a syringe plunger was used to further disrupt the tissue by 
filtering through a 70 µm mesh. Cells were washed once with PBS. Red blood cells (RBC) were 
lysed using RBC lysis buffer (Biolegend) according to the manufacturers instructions. Casy 
counter (Innovatis) was used to determine cell numbers. 
4.3.8 Flow cytometry analysis of murine splenocytes and LN cells
For the analysis of cell surface antigens, 2 x 107 cells were resuspended in 25 µl PBS and an equal 
volume of two-fold concentrated antibody solution was added. After incubation on ice for 30 
minutes, cells were washed twice with 200 µl PBS before acquisition. For intracellular cytokine 
staining, 2 x 107 cells were incubated per well of a 96-well V bottom plate in 100 µl RPMI-1640 
containing 10 % FCS, 50 ng/ml PMA, 500 ng/ml Ionomycin and 10 µg/ml Brefeldin A (Sigma) 
for 4 hours at 37 °C and 5 % CO2 in a humidified incubator. For intracellular detection of 
cytokines and transcription factors, FoxP3 transcription factor staining buffer set (eBioscience) 
was used according to the manufacturers instructions. Fluorochrome labeled antibodies were 
purchased from Biologend (anti-CD8a-FITC or -BV785 (clone 53-6.7), anti-CD11b-APC-
Cy7 (clone M1/70), anti-CD11c-PE-Cy7 (clone N418), anti-CD25-BV605 (clone PC61), anti-
CD44-Pacific Blue (clone IM7), anti-CD80-PE (clone 16-10A1), anti-IL-17a-PE-Cy7 (clone 
TC11-18H10), anti-IFN-g-FITC (clone XMG1.2), anti-Ly6C-PerCp-Cy5.5 (clone HK1.4), 
anti-Ly6G-APC (clone 1A8) and anti-MHC-II-Pacific Blue (I-A/I-E, clone M5/114.15.2)) and 
eBioscience (anti-CD19-Alexa-Fluor700 (clone eBio1D3 (1D3), anti-FoxP3-PerCp-Cy5.5 
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(clone FJK-16s) and anti-GM-CSF-PE (clone MP1-22E9)) and BD Pharmingen (anti-CD4-
APC (clone RM4-5) and anti-CD62L-PE-CF594 (clone MEL-14)). Fixable L/D staining kits 
(aqua/amcyan and near-IR) were purchased from Invitrogen. Samples were acquired using BD 
LSR Fortessa (see table 4.2 for optical configuration).
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Abbreviations:
AAL  Aleuria aurantia lectin
ADCC  Antibody-dependent cell-mediated cytotoxicity
ADCP  Antibody-dependent cell-mediated phagocytosis
AID  Activation-induced deaminase
APC  Antigen presenting cell
b1,4GalT β1,4 galactosyltransferase-1
B6 mice C57BL/6 mice
BCR  B cell receptor
C  Cytosine
CCR  CC chemokine receptor
CD  Cluster of differentiation
CDC  Complement-dependent cytotoxicity
CDR  Complementary determining region
cDNA  Complementary DNA
CHO  Chinese hamster ovary 
CIDP  Chronic inflammatory demyelinating polyneuropathy
CL  Constant region, light chain
CNS  Central nervous system
CH  Constant region, heavy chain
CFA  Complete Freund’s adjuvant
CR  Complement receptor
CTL  Cytotoxic T lymphocyte
DC-SIGN DC-specific intercellular adhesion molecule-3-grabbing non-integrin
dLNs  Draining lymph nodes
DNA  Deoxyribonucleic acid
EAE  Experimental autoimmune encephalomyelitis
EC50  Half maximal effective concentration
ECL  Erythrina cristagalli lectin
ELISA  Enzyme-linked Immunosorbent Assay
EndoS  Endoglycosidase from Streptococcus pyogenes
FCS  Fetal calf serum
H  Histidine
hu8-18C5 Humanized 8-18C5 antibody
N-glycan Asparagine-glycan
ER  Endoplasmatic reticulum
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HC  Heavy chain 
HEK293T Human embryonic kidney cells containing the SV40 Large T-antigen
DC  Dendritic cell
F  Phenylalanine
Fab  Fragment antigen binding
F(ab’)2  Fragment antigen binding (disulfide-linked dimer)
FACS  Fluorescence-activated cell sorting
Fc  Fragment crystallizable 
FcgR  Fcg receptor
FcRn  Neonatal Fc receptor
FSC  Forward scatter
FSC-A  FSC-area
FCS-H  FSC-height
Fuc  Fucose
Gal  Galactose
GlcNAc N-acetylglucosamine
GM-CSF Granulocyte-macrophage colony stimulating factor
I  Isoleucine
i.p.  intraperitoneal
Ig  Immunoglobulin
IgA  Immunoglobulin A
IgD  Immunoglobulin D
IgE  Immunoglobulin E
IgG  Immunoglobulin G
IgM  Immunoglobulin M
IFN  Interferon
IL  Interleukin
ITAM  Immunoreceptor tyrosin-based activation motif
ITIM  Immunoreceptor tyrosin-based inhibitory motif
ITP  Idiopathic thrombocytopenic purpura
IU  International units
IVIG  Intravenous Immunoglobulin
LC  Light chain 
LCA  Lens culinaris agglutinin 
LN  Lymph node
mRNA  Messenger RNA
Man  Mannose
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MBL  Mannose-binding lectin
MBP  Myelin basic protein
MFI  Median fluorescence intensity
MHC  Major histocompatibility complex
MMN  Multifocal motor neuropathy
MOG  Myelin oligodendrocyte glycoprotein
N  Asparagine
NK   Natural killer cell
PAMP  Pathogen associated molecular patterns
PBMC  Peripheral blood mononuclear cells
PBS  Phosphate buffered saline
PAGE  Polyacrylamide gel electrophoresis
PMA  Phorbol myristate acetate
Q  Glutamine
R  Arginine
RA  Rheumatoid arthritis
RNA  Ribonucleic acid
rpm  Rotations per minute
RTX  Rituximab
SDS  Sodium dodecyl sulfate
SEM  Standard error of the mean
SHM  Somatic hypermutation
SIGLEC Sialic acid-binding immunoglobulin-type lectins
SLE  Systemic lupus erythematosus
SNA  Sambucus nigra agglutinin
SNP  Single-nucleotide polymorphism
ST6Gal1 α2,6-sialyltransferase
SSC-A  Side scatter area
T  Threonine (proteins)
T  Thymidine (DNA)
TBS  Tris buffered saline
TCR  T cell receptor
Tregs  Regulatory T cells
U  Uracil
V(D)J  Variable, diversity and joining elements
VH  Variable region, heavy chain
VL  Variable region, light chain
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